Healio Minute: Recent Episodes
Healio
Welcome to the "Healio Minute" podcast. This is a look at some of the trending headlines in the field of Orthopedics.
I'm your host, Erin Welsh. In this edition, we look at an excerpt from a recent Beneath the Surface podcast, graft-versus-host disease, topical gel and more.
In this edition, we look at frailty as a predictor of fractures, predictors of pain in rheumatoid arthritis and more.
Read the full coverage here:
Frailty may predict osteoporotic fracture in US veterans with rheumatoid arthritis
Factors unrelated to inflammation may contribute to unacceptable rheumatoid arthritis pain
US House committee opens investigations into five drugmakers over clinical trials in China
Survey shows high variability in cannabis use across patients with rheumatic disease
New England Journal of Medicine retracts avacopan study used by FDA to assess efficacy
In this edition, we look at the brain-immune axis, EULAR updates and more.
Read the full coverage here:
'Brain-immune axis' implicated in simultaneous inflammation and depression, mood disorders
EULAR updates physical activity recommendations for inflammatory arthritis, OA
Study demonstrates proof-of-concept for FcRn blocker nipocalimab in lupus
'Uniquely structured' izokibep improves skin, disease activity in psoriatic arthritis
Dual-target CAR T-cell therapy exhibits 'profound' remission in systemic sclerosis
References:
Calabrese L. The science of the connection: Inflammation and mental health. Presented at: EULAR 2026 Congress; June 3-6, 2026, London.
Furie RA. Abstract LB007. Presented at: EULAR 2026 Congress; June 3-6, 2026, London.
Mease PJ. Abstract OP073. Presented at: EULAR 2026 Congress; June 3-6, 2026, London.
Rausch Osthoff AK, et al. Ann Rheum Dis. 2026;doi:10.1016/j.ard.2026.03.006.
Zhang Y. Abstract OP0311. Presented at: EULAR 2026 Congress; June 3-6, 2026, London.
In this edition, we look at new EAULAR recommendations for rheumatoid arthritis, the vagal nerve and more.
Read the full coverage here:
New EULAR recommendations for rheumatoid arthritis keep pace with 'ever-evolving field'
Calabrese: Vagal nerve stimulation a 'tectonic shift' in rheumatoid arthritis management
FDA grants fast track designation to intra-articular GLP-1 analog for knee osteoarthritis
Lupus prevention remains elusive despite new treatments
New agents, combinations make for 'exciting time' in psoriatic arthritis
References:
Calabrese LH. Psychoneuroimmunology 101; How will vagal nerve stimulation affect the rheumatologist's practice. Presented at The Congress of Clinical Rheumatology East; April 30-May 3, 2026; Destin, Florida (hybrid meeting).
Healio interviews
Healio interviews
James JA. Novel treatments for systemic lupus erythematosus. Presented at: Congress of Clinical Rheumatology East; April 30-May 3, 2026; Destin, Florida (hybrid meeting).
Kavanaugh A. Achieving precision medicine in PsA: Novel treatment strategies. Presented at The Congress of Clinical Rheumatology East; April 30-May 3, 2026; Destin, Florida (hybrid meeting).
In this edition, we look at rheumatology visits impacting reproductive health counseling, restrictive Medicare Part D coverage, and more.
Read the full coverage here:
Services targeting rheumatology visits increased reproductive health counseling rates 625%
Medicare Part D coverage of certain rheumatoid arthritis drugs 'restrictive'
DMARD treatment fails to mitigate osteoporosis in rheumatoid arthritis
FDA to 'carefully shepherd' CAR T-cell therapy trials in autoimmune, rheumatic disease
Low pay, longer training requirements hobble pediatric rheumatology workforce numbers
References:
Aritomi T, et al. Arthritis Rheumatol. 2026;doi:10.1002/art.70125.
Healio interviews
Healio interviews
Kwon Y, et al. Arthritis Rheumatol. 2026;doi:10.1002/art.70132.
Marcy D, et al. Arthritis Care Res. 2026;doi:10.1002/acr.80014.
In this edition, we look at the impact of GLP-1s on total joint replacement, the safety of NSAID's and more.
Read the full coverage here:
GLP-1s may have profound impact on total joint replacement
NSAID use may be safe prior to total joint arthroplasty
Complication risk may be lower for revision TJA when performed in ASC
Despite improved function, patients with elbow dislocation often report long-term pain
Osteochondral allograft transplant may treat pediatric elbow osteochondritis dissecans
References:
Acuña AJ, et al. Paper 33. Presented at: American Association of Hip and Knee Surgeons Annual Meeting; Oct. 23-26, 2025; Dallas.
Foran JRH, et al. Paper 31. Presented at: American Association of Hip and Knee Surgeons Annual Meeting; Oct. 23-26, 2025; Dallas.
Healio Interviews
Perkins CA, et al. Am J Sports Med. 2025;doi:10.1177/03635465251366903.
Plaisier N, et al. Paper 29. Presented at: Orthopaedic Trauma Association Annual Meeting; Oct. 15-18, 2025; Phoenix.
In this edition, immunotherapy in advanced lung cancer, updates in EGFR-mutated lung cancer and more. Read the full coverage here:
VIDEO: Immunotherapy in advanced lung cancer among highlights from ESMO 2025
VIDEO: Updates in EGFR-mutated lung cancer from ESMO 2025
VIDEO: DeLLphi-303 results show 'major jump in survival' for SCLC patients Emphysema found during lung cancer screening raises risk for mortality Q&A: More nonsmokers developing lung cancer due to radon exposure, air pollution References
· González Gutiérrez J, et al. Radiology. 2025;doi:10.1148/radiol.250949.
· Healio Interviews
· Healio Interviews
· Healio Interviews
· Paulson KG, et al. Abstract OA13.01. Presented at IASLC World Conference on Lung Cancer; Sept. 6-9, 2025; Barcelona.
In this edition, we look at robotic-assisted surgery, dislocation risk in fixed-bearing THA and more.
Read the full coverage here:
Higher head-to-cup ratio, robotic-assisted surgery may lower dislocation rate after THA
Fully maximizing bearing diameter may reduce dislocation risk in fixed-bearing THA
How may GLP-1s impact nutrition prior to orthopedic surgery?
Medicare contractors propose coverage restriction of peripheral nerve block procedures
Physician content on TikTok may guide patient education
References:
Expert submission
Healio Interviews
Healio Interviews
Kobayashi JK, et al. Paper 54. Presented at: American Association of Hip and Knee Surgeons Annual Meeting; Oct. 23-26, 2025; Dallas.
Wang E, et al. Maximizing bearing diameter markedly lowers dislocations in primary total hip arthroplasty. Presented at: American Association of Hip and Knee Surgeons Annual Meeting; Oct. 23-26, 2025; Dallas.
In this edition, FDA warns complications following radiofrequency microneedling device use, chronic hand eczema considered "common" disease, and more. Read the full coverage here:
Q&A: FDA warns of radiofrequency microneedling risks; here's what to know
Chronic hand eczema now considered a 'common' skin disease in US
'Unproven' topical estrogens for the face may bring some risks
FDA approves Restylane Lyft to treat receding chin
References
Chovatiya R, et al. Prevalence of self-reported physician diagnosis of chronic hand eczema in adults: A cross-sectional study of more than 10,000 participants in the general population – Results from the CHECK study in the United States. Presented at: Fall Clinical Dermatology Conference; Oct. 23-26, 2025; Las Vegas.
Farkas E, et al J Am Acad Dermatol. 2025;doi:10.1016/j.jaad.2025.08.050.
Healio Interviews
Press Release
In this edition, we look at rehabilitation protocols, how AI can help patients with total knee arthroplasty, synthetic THC and more.
Read the full coverage here:
'Quiet knee' rehabilitation protocol may reduce opioid exposure after TKA
AI-enabled decision aid may improve TKA decision-making
Synthetic THC may not reduce opioid intake after TKA
Lorecivivint yields 'meaningful' improvements in knee osteoarthritis at 1 year
Corticosteroid injections yield 'disappointing' response in knee osteoarthritis
References:
Baker J. Abstract 2624. Presented at: ACR Convergence 2025; Oct 24-29, 2025; Chicago.
Bhatti P, et al. Poster 30. Presented at: American Association of Hip and Knee Surgeons Annual Meeting; Oct. 23-26, 2025; Dallas.
Jayakumar P, et al. Paper 30. Presented at: American Association of Hip and Knee Surgeons Annual Meeting; Oct. 23-26, 2025; Dallas.
Jennings JM, et al. Paper 10. Presented at: American Association of Hip and Knee Surgeons Annual Meeting; Oct. 23-26, 2025; Dallas.
Yazici Y. Abstract 2626. Presented at: ACR Convergence 2025; Oct 24-29, 2025; Chicago.
In this edition, Congress reintroduces the Safe Step Act, an expert expresses doubt about the benefits of TrumpRx and more. Read the full coverage here:
Congress reintroduces Safe Step Act to amend step therapy policies
Q&A: TrumpRx, Pfizer deal sidestep health insurance companies
Complete hair regrowth for some with alopecia after 3-year ritlecitinib treatment
Waterproof bandages 'reasonable alternative' to petroleum-based wound care
References
· Bell MC, et al JAMA Dermatol. 2026;doi:10.1001/jamadermatol.2025.4051.
· Healio Interviews
· King B, et al. Abstract #LBA-335. Presented at: European Academy of Dermatology and Venereology Congress; Sept. 17-20, 2025; Paris.
In this edition, increased lung cancer screening improving outcomes, overall survival data from FLAURA2 trial and more. Read the full coverage here:
Increased lung cancer screening improving outcomes, but rates 'still too low'
VIDEO: Overall survival data from FLAURA2 trial presented at WCLC
Updated NCCN guidelines on NSCLC put spotlight on biomarker testing 'Never too late': Smoking cessation after cancer diagnosis can extend survival New treatments worsened income-based survival disparities for lung cancer, melanoma References
· American Lung Association 2025 State of Lung Cancer.
· Khor S, et al. JCO Oncol Adv. 2025;doi:10.1200/OA-25-00026.
· National Comprehensive Cancer Network.
· Planchard D, et al. Abstract PL02.06. Presented at IASLC World Conference on Lung Cancer; Sept. 6-9, 2025; Barcelona.
· Tohmasi S, et al. J Natl Compr Canc Netw. 2025;doi:10.6004/jnccn.2025.7059.
In this edition, we look at the first FDA approval of an oral therapy for chronic spontaneous urticaria, and more.
Read the full coverage here:
FDA approves first oral therapy for chronic spontaneous urticaria
Denifanstat safe, effective in acne vulgaris treatment
FDA approves Zoryve cream 0.05% for pediatric atopic dermatitis
The 'Zoom boom' effect: Post-pandemic cost concerns for facial cosmetic procedures
References:
F Xiang, et al. Abstract #LBA-213. Presented at: European Academy of Dermatology and Venereology Congress; Sept. 17-20, 2025; Paris.
Pecora V, et al. J Drugs Dermatol. 2025;doi:10.36849/JDD.9102.
Press Release
Press Release
In this edition, we look at how AI can help patients with total joint arthroplasty, the impact of opioid use on in-hospital sleep and more.
Read the full coverage here:
Custom-tailored AI platform may be feasible for addressing patient questions before TJA
Opioid use may negatively affect in-hospital sleep, orthopedic trauma outcomes
Polymicrobial infection may predict septic long bone nonunion repair reoperation
Patients recognize importance of nutrition after surgery, need help with implementation
GLP-1s may offer a 'protective effect' in shoulder surgery for patients with diabetes
References:
Barth K, et al. Paper 63. Presented at: Orthopaedic Trauma Association Annual Meeting; Oct. 15-18, 2025; Phoenix.
Martiono JA, et al. Paper 1. Presented at: American Shoulder and Elbow Surgeons Annual Meeting; Oct. 15-18, 2025; San Diego.
Rizk AA, et al. Paper 4. Presented at: American Shoulder and Elbow Surgeons Annual Meeting; Oct. 15-18, 2025; San Diego.
Schenker ML, et al. Paper 65. Presented at: Orthopaedic Trauma Association Annual Meeting; Oct. 15-18, 2025; Phoenix.
Zepeda KE, et al. Poster 13. Presented at: American Association of Hip and Knee Surgeons Annual Meeting; Oct. 23-26, 2025; Dallas.
In this edition we look at hip fracture surgery delays, how homelessness affects hip surgery outcomes and more.
Read the full coverage here:
Hip fracture surgery delay may increase mortality risk
Homelessness may be a predictor of poor outcomes following hip fracture surgery
Biological age, age acceleration may predict 1-year mortality after geriatric hip fracture
Hip resurfacing device had low all-cause revision rate at 8-year follow-up
Group cycling program leads to 'meaningful benefit' in hip osteoarthritis
References:
Cobb JP. Paper 11. Presented at: American Association of Hip and Knee Surgeons Annual Meeting; Oct 23-26, 2025; Dallas.
Healio interviews
Hoveidaei AH, et al. Paper 7. Presented at: Orthopaedic Trauma Association Annual Meeting; Oct. 15-18, 2025; Phoenix.
King SW, et al. Hip fracture surgery delayed by operating room capacity is an independent risk factor for 120-day mortality. Presented at: Orthopaedic Trauma Association Annual Meeting; Oct. 15-18, 2025; Phoenix.
Randall Z, et al. Paper 2. Presented at: Orthopaedic Trauma Association Annual Meeting; Oct. 15-18, 2025; Phoenix.
In this edition, FDA approves golimumab for pediatric ulcerative colitis, hospital affiliation linked to higher-cost care and more. Read the full coverage here:
FDA approves golimumab for pediatric ulcerative colitis
'Tremendous implications': Hospital affiliation linked to higher-cost care
'Set a 2-TikTok limit': Smartphone use on toilet linked to higher risk for hemorrhoids
APPs step up to fill GI care gaps, but scant on-the-job training fuels own burnout
Rideshare 'potentially scalable intervention' to improve colonoscopy after abnormal FIT
References:
Expert Submission
Issaka RB, et al. JAMA Netw Open. 2025;doi:10.1001/jamanetworkopen.2025.30515.
Kapoor DA et al. J Mark Access Health Policy. 2025;doi:10.3390/jmahp13030036.
Press Release
Ramprasad C, et al. PLoS One. 2025;doi:10.1371/journal.pone.0329983.
In this edition, radiation is a 'strong alternative' for surgery, FDA approves combination therapy for small cell lung cancer and more.
Read the full coverage here:
Radiation a 'strong alternative' to surgery for early-stage lung cancer
FDA approves lurbinectedin, atezolizumab combination for small cell lung cancer
Diagnostic yield high with robotic-assisted bronchoscopy in peripheral lung lesions
Machine learning model predicts urgent care visits during lung cancer treatment
Evidence is 'clear': Medicaid expansion significantly improves long-term cancer survival
References:
Gonzalez BD, et al. JCO Clin Cancer Inform. 2025;doi:10.1200/CCI-24-00315.
Kleber T, et al. Abstract 268. Presented at: ASTRO Annual Meeting; Sept. 27-Oct. 1, 2025; San Francisco.
Press Release
Schafer EJ, et al. Cancer Discov. 2025;doi:10.1158/2159-8290.CD-25-1244.
Steinack C, et al. OA1178: Robotic-assisted bronchoscopy with integrated cone-beam CT vs. conventional bronchoscopy for diagnosing peripheral pulmonary lesions: An open-label randomized controlled trial. Presented at: European Respiratory Society International Congress; Sept. 27-Oct. 1, 2025; Amsterdam.
In this edition, bioinductive implants for ACL reconstruction, osteochondral defects treatments and more.
Read the full coverage here:
ACL reconstruction with reinforced bioinductive implant may yield favorable outcomes
Multiplug, single-plug techniques had comparable outcomes for osteochondral defects
MRI-based clinical prediction model identified risk factors for patellar instability
New technology, cost strategies continue to move robotic-assisted surgery forward
Physician referral to physical therapy underutilized for patients with knee osteoarthritis
References:
Healio Interviews
Khoja SS, et al. Arthritis Care Res. 2025;doi:10.1002/acr.25630.
McMillan S, et al. Surg Technol Int. 2025;doi:10.52198/25.STI.45.OS1888.
Mufti YN, et al. Am J Sports Med. 2025;doi:10.1177/03635465251352172.
Nukala V, et al. Arthrosc Sports Med Rehabil. 2025;doi:10.1016/j.asmr.2025.101159.
In this edition, we look at AI bias, nonsurgical biologic therapies and more.
Read the full coverage here:
‘Math, not magic’: Identify and combat bias in AI
Orthobiologics: Commit to evidence-based practice, foster cautious optimism
TJR indications expand, making it a young man’s game
Successful management of PJI occurred in about 50% of patients
Risks of anteromedial tibial tubercle transfer are minimal and the benefits great
References:
Expert Submission
Healio Interviews
Higuera Rueda C, et al. Paper 1409. Presented at: Musculoskeletal Infection Society Annual Meeting; Aug. 1-2, 2025; Jersey City, N.J.
Engagement Time: 18 minutes
In this edition, FDA approves subcutaneous chemotherapy for solid tumors, improvements to shared decision-making and more.
Read the full coverage here:
FDA approves Hernexeos as first oral therapy for NSCLC with HER2 mutations
Communication, knowledge critical to improve shared decision-making for lung cancer
Detection of ctDNA could help determine use of immunotherapy for small cell lung cancer
Subcutaneous amivantamab plus lazertinib produces similar results to IV regimen in NSCLC
Lung cancer screening guidance needed for certain never-smokers
References:
Bi N, et al. Abstract 2034. Presented at IASLC World Conference on Lung Cancer; Sept. 6-9, 2025; Barcelona.
Press Release
Scott SC, et al. Abstract 1798. Presented at IASLC World Conference on Lung Cancer; Sept. 6-9, 2025; Barcelona.
Shum E, et al. Abstract 2172. Presented at IASLC World Conference on Lung Cancer; Sept. 6-9, 2025; Barcelona.
Villalon D, et al. Abstract 2368. Presented at IASLC World Conference on Lung Cancer; Sept. 6-9, 2025; Barcelona.
In this edition, ultra-processed grains linked to elevated risk for IBD, CTA use for GI bleeds increase and more.
Read the full coverage here:
Ultra-processed grains linked to elevated risk for IBD, especially ulcerative colitis
‘Double whammy:’ CTA use for GI bleeds rise, but diagnostic yield drops
‘Another layer of benefit’: GLP-1s linked to lower risk for peptic ulcer disease
‘Simplified care models’ needed for chronic HBV care to meet 2030 global elimination goals
‘Stay vigilant’: Routine exposure to AI may reduce ADR in standard colonoscopy
References:
Budzyń K, et al. Lancet Gastroenterol Hepatol. 2025;doi:10.1016/S2468-1253 (25) 00133-5.
Narula N, et al. Am J Gastro. 2025;doi:10.14309/ajg.0000000000003700.
Prasad S, et al. JAMA Netw Open. 2025;doi:10.1001/jamanetworkopen.2025.29746.
Seika P, et al. Clin Gastroenterol Hepatol. 2025;doi:10.1016/j.cgh.2025.08.015.
Stockdale AJ, et al. Lancet Gastroenterol Hepatol. 2025;doi:10.1016/S2468-1253(25)00163-3.
In this edition, we look at labral reconstruction in adolescents, the risk of skipping breakfast on osteoporotic fractures and more.
Read the full coverage here:
Labral reconstruction yielded favorable outcomes among adolescent patients
Skipping breakfast, eating late dinners may raise risk for major osteoporotic fractures
AI may personalize patient care, identify surgical risks
Surgical fixation for pickleball-related Achilles ruptures may improve quality of life
Screening for osteoporosis, preventing fractures essential in diabetes care
References:
Chen C, et al. Paper 17. Presented at: American Orthopaedic Society for Sports Medicine Annual Meeting; July 10-12, 2025; Nashville, Tenn
Domb BG, et al. Paper 50. Presented at: American Orthopaedic Society for Sports Medicine Annual Meeting; July 10-12, 2025; Nashville, Tenn.
Kemmis K. Presentation D27. Presented at: ADCES25; Aug. 8-11, 2025; Phoenix.
Nakajima H, et al. J Endocr Soc. 2025;doi:10.1210/jendso/bvaf127.
Weight C. AI in the OR: Personalizing care, lowering complications and automating surgery. Presented at: Cleveland Clinic’s A.I. Summit for Healthcare Professionals; July 11, 2025; Cleveland.
In this edition, we look at the risk orthopedic surgeons face from insufficient malpractice coverage, the role of AI in osteoporosis and more.
Read the full coverage here:
AI-assisted diagnostic system may identify osteopenia, osteoporosis
Insufficient malpractice coverage may place surgeons caring for elite athletes at risk
Psychological readiness, stress improved 2 years after ACL reconstruction
Patella resurfacing reduced maltracking, had comparable outcomes as nonresurfacing
Patellofemoral osteochondral allograft transplantation may effectively treat lesions
References:
Jolissaint JE, et al. Paper 1538. Presented at: Musculoskeletal Infection Society Annual Meeting; Aug. 1-2, 2025; Jersey City, N.J.
Milewski MD, et al. Paper 57. Presented at: American Orthopaedic Society for Sports Medicine Annual Meeting; July 10-12, 2025; Nashville, Tenn.
Moro T, et al. J Orthop Res. 2025;doi:10.1002/jor.70000.
Ramkumar PN, et al. Paper 37. Presented at: American Orthopaedic Society for Sports Medicine Annual Meeting; July 10-13, 2025; Nashville, Tenn.
Wang T, et al. Paper 28. Presented at: American Orthopaedic Society for Sports Medicine Annual Meeting; July 10-12, 2025; Nashville, Tenn.
In this edition, FDA approves first oral therapy for NSCLC, interstitial lung disease diagnosis raises risk for lung cancer and more.
Read the full coverage here:
FDA approves Hernexeos as first oral therapy for NSCLC with HER2 mutations
ILD diagnosis raises risk for lung cancer
Uninsured patients benefit less from immune checkpoint inhibitors than privately insured
Shared decision-making visit improves annual lung cancer screening adherence
Indoor tobacco, e-cigarette use more common in rural vs. urban homes
References:
Chung Y, et al. CHEST. 2025;doi:10.1016/j.chest.2025.06.026.
Press Release
Steinberg AW, et al. Ann Am Thorac Soc. 2025;doi:10.1513/AnnalsATS.202504-419OC.
Xu H, et al. JAMA Netw Open. 2025;doi:10.1001/jamanetworkopen.2025.19630.
Zhao J, et al. JAMA Netw Open. 2025;doi:10.1001/jamanetworkopen.2025.19274.
In this edition, opioid deaths with GI issues tripled in the past decade, prophylactic vancomycin may reduce risk for recurrent C. difficile and more.
Read the full coverage here:
‘Deeply alarming’: Opioid deaths with GI issues tripled in the past decade
Prophylactic vancomycin may reduce risk for recurrent C. difficile
CRC disparities in Black communities stem from access, not biology, experts say
Mediterranean, plant-based diets linked to lower risk for chronic constipation
Psychiatric disorders ‘common’ among patients with inflammatory bowel disease
References:
Appiah JK, et al. Cureus. 2025;doi:10.7759/cureus.86489.
Cadogan K, et al. Crohns Colitis 360. 2025;doi:10.1093/crocol/otaf035.
Keating JA, et al. JAMA Netw Open. 2025;doi:10.1001/jamanetworkopen.2025.17834.
May FP, et al. Nat Rev Gastroenterol Hepatol. 2025;doi: 10.1038/s41575-025-01087-3.
Wang Y, et al. Gastroenterology. 2025;doi:10.1053/j.gastro.2025.06.020.
In this edition, we look at how state opioid cap laws impact total joint replacements, how nutrition affects orthopedic surgery and more.
Read the full coverage here:
State opioid cap laws may reduce opioid fills after total joint replacement
Nutrition may be key to muscle, bone health after surgery
Should malnutrition screening occur before orthopedic surgery?
Pyrocarbon hemiarthroplasty with glenoid reaming may improve outcomes for young patients
Physicians under pressure in name, image and likeness era
References:
Expert Submission
Healio Interviews
Healio Interviews
Ranieri R, et al. J Shoulder Elbow Surg. 2025;doi:10.1016/j.jse.2024.06.028.
Thirukumaran CP, et al. JAMA Netw Open. 2025;doi:10.1001/jamanetworkopen.2025.4448.
In this edition, we look at how testosterone and exercise affect older women with hip fracture, how vitamin C may be an effective alternative to glucocorticoids and more.
Read the full coverage here:
Function not improved with testosterone plus exercise after hip fracture in older women
Vitamin C may be effective alternative to glucocorticoids in total hip arthroplasty
Hip resurfacing may be effective for younger, active men with osteoarthritis
Robotic-assisted THA may reduce opioid requirements vs. manual, computer-assisted THA
One-stage exchange may provide alternative for chronic PJI
References:
Binder EF, et al. JAMA Netw Open. 2025;doi:10.1001/jamanetworkopen.2025.10512.
Expert Submission
Giannakis P, et al. e-Poster 6833. Presented at: Anesthesiology and Acute Pain Medicine Meeting; May 1-3, 2025; Orlando.
Jiang W, et al. J Bone Joint Surg Am. 2025;doi:10.2106/JBJS.24.01080.
Zuke WA, et al. J Bone Joint Surg Am. 2025;doi:10.2106/JBJS.24.00926.
In this edition, light physical activity linked to lower cancer risk, lung lesion diagnostic yield from bronchoscopy and more.
Read the full coverage here:
‘Every bit of movement counts’: Even light physical activity linked to lower cancer risk
Robotic, electromagnetic navigation bronchoscopy have similar lung lesion diagnostic yield
Women with history of adverse pregnancy outcomes face elevated risk for future COPD
Long-term blood pressure lowering does not appear to impact risk for new-onset cancer
Most patients with advanced cancer do not undergo next-generation sequencing testing
References:
Chehade CH, et al. Abstract 11014. Presented at: ASCO Annual Meeting; May 30-June 3, 2025; Chicago.
Paez R, et al. Am J Respir Crit Care Med. 2025;doi:10.1164/rccm.202409-1846OC.
Shreves AH, et al. Br J Sports Med. 2025;doi:10.1136/bjsports-2024-109360.
Sridhar S, et al. Adverse pregnancy outcomes and future maternal risk of developing COPD: An analysis of the Women’s Health Initiative. Presented at: American Thoracic Society International Conference; May 16-21, 2025; San Francisco.
Zazarzadeh M, et al. JACC CardioOncol. 2025;doi:10.1016/j.jaccao.2025.03.005.
In this edition, IBD social risks linked to unplanned ED use, anal cancer screening for men with HIV may cut deaths by 65% and more.
Read the full coverage here:
Nearly two-thirds of adults with IBD experience social risks linked to unplanned ED use
Anal cancer screening at age 35 for gay, bisexual men with HIV may cut deaths by 65%
‘Not just a physical issue’: CRC linked to adverse sexual health outcomes among women
‘We need to take ownership’: ACG guideline urges preventive care in IBD management
Managing gut dysbiosis may offer ‘therapeutic window’ for severe alcoholic hepatitis
References:
Deshmukh AA, et al. Ann Intern Med. 2025;doi:10.7326/ANNALS-24-01426.
Farraye FA, et al. Am J Gastroenterol. 2025;doi:10.14309/ajg.0000000000003541.
Kim S, et al. Clin Gastroenterol Hepatol. 2025;doi:10.1016/j.cgh.2025.03.031.
Oveisi N, et al. J Natl Cancer Inst. 2025;doi:10.1093/jnci/djaf120.
Vaithiyam V, et al. Cureus. 2025;doi:10.7759/cureus.85516.
In this edition, we look at knee replacement survivorship, how DEI statements may lead to more women in sports medicine programs and more.
Read the full coverage here:
Public DEI statements may lead to more women faculty, fellows in sports medicine programs
Knee replacements have high long-term survivorship in young patients
Aragonite-based scaffold yielded similar outcomes between men, women with chondral defects
Platelet-rich plasma may be inferior to corticosteroid injections for knee osteoarthritis
Bioinductive collagen implant had similar outcomes as suture anchors in rotator cuff tears
References:
Hurley ET, et al. Clinical outcomes of bioinductive collagen implants for high-grade partial rotator cuff tears. Presented at: Arthroscopy Association of North America Annual Meeting; May 8-10, 2025; Washington, D.C
Kon E, et al. Female patients report comparable results to males after the implantation of an aragonite scaffold. Presented at: Arthroscopy Association of North America Annual Meeting; May 8-10, 2025; Washington, D.C.
Pai J, et al. Diversity, equity and inclusion initiatives and faculty roles in orthopedic sports fellowship. Presented at: Arthroscopy Association of North America Annual Meeting; May 8-10, 2025; Washington, D.C.
Swartz GN, et al. Poster e251. Presented at: American Academy of Orthopaedic Surgeons Annual Meeting; March 10-14, 2025; San Diego.
Weinblatt AI, et al. Paper 416. Presented at: American Academy of Orthopaedic Surgeons Annual Meeting; March 10-14, 2025; San Diego.
In this edition, DREAM program ‘better than anything’ available, maintenance regimen a potential new standard and more.
Read the full coverage here:
DREAM program ‘better than anything’ available for patients with advanced lung cancer
Maintenance regimen a potential new standard in extensive-stage small cell lung cancer
‘It can save their lives’: Annual lung cancer screening improves cancer detection rate
Assay predicts adjuvant chemotherapy benefit in early-stage non-small cell lung cancer
High environmental burden has associations with incidence of multiple cancer types
References:
Kamarei AMA, et al. Abstract 11009. Presented at: ASCO Annual Meeting; May 30-June 3, 2025; Chicago.
Kim RY, et al. JAMA Netw Open. 2025;doi:10.1001/jamanetworkopen.2025.0942.
Paz-Ares LG, et al. Abstract #8006. Presented at: ASCO Annual Meeting; May 30-June 3, 2025; Chicago.
Press Release
Spigel DR, et al. Abstract LBA8027. Presented at: ASCO Annual Meeting; May 30-June 3, 2025; Chicago.
In this edition, reduction efforts prevent 3.8 million lung cancer deaths since 1970, first-line combination should be ‘new standard’ in advanced lung cancer and more.
Read the full coverage here:
Smoking cessation, reduction efforts prevent 3.8 million lung cancer deaths since 1970
First-line combination should be ‘new standard’ in advanced lung cancer
Only 1 in 5 people treated with immune checkpoint inhibitors respond to therapy
‘It can save their lives’: Annual lung cancer screening improves cancer detection rate
‘Are we giving false hope?’: Few hospitalized people with cancer benefit from immunotherapy
References:
Haslam A, et al. Int J Cancer. 2025;doi:10.1002/ijc.35347.
Islami F, et al. CA Cancer J Clin. 2025;doi:10.3322/caac.70005.
Kim RY, et al. JAMA Netw Open. 2025;doi:10.1001/jamanetworkopen.2025.0942.
Riaz F, et al. JCO Oncol Pract. 2025;doi:10.1200/OP-24-00788.
Yang JCH, et al. Amivantamab plus lazertinib vs osimertinib in first-line EGFR-mutant advanced NSCLC. Presented at: European Lung Cancer Congress; March 26-29, 2025; Paris.
In this edition, reduction efforts prevent 3.8 million lung cancer deaths since 1970, first-line combination should be ‘new standard’ in advanced lung cancer and more.
Read the full coverage here:
Smoking cessation, reduction efforts prevent 3.8 million lung cancer deaths since 1970
First-line combination should be ‘new standard’ in advanced lung cancer
Only 1 in 5 people treated with immune checkpoint inhibitors respond to therapy
‘It can save their lives’: Annual lung cancer screening improves cancer detection rate
‘Are we giving false hope?’: Few hospitalized people with cancer benefit from immunotherapy
References:
Haslam A, et al. Int J Cancer. 2025;doi:10.1002/ijc.35347.
Islami F, et al. CA Cancer J Clin. 2025;doi:10.3322/caac.70005.
Kim RY, et al. JAMA Netw Open. 2025;doi:10.1001/jamanetworkopen.2025.0942.
Riaz F, et al. JCO Oncol Pract. 2025;doi:10.1200/OP-24-00788.
Yang JCH, et al. Amivantamab plus lazertinib vs osimertinib in first-line EGFR-mutant advanced NSCLC. Presented at: European Lung Cancer Congress; March 26-29, 2025; Paris.
In this edition, sick food service workers top driver of viral foodborne outbreaks in US, no weight loss benefit with semaglutide before bariatric surgery and more.
Read the full coverage here:
Sick food service workers remain top driver of viral foodborne outbreaks in US
‘We have work to do’: No weight loss benefit with semaglutide before bariatric surgery
Mailed FIT outreach program boosts colorectal cancer screening in rural areas
‘Distinct viral exposure patterns’ found in patients with Crohn’s years before diagnosis
Mortality, dropout risk higher on liver transplant waitlist in low-density areas
References:
Coronado GD, et al. JAMA Netw Open. 2025;doi:10.1001/jamanetworkopen.2025.0928.
Holst MM, et al. MMWR Surveill Summ. 2025;doi:10.15585/mmwr.ss7401a1.
Mathur V, et al. JAMA Surg. 2025;doi:10.1001/jamasurg.2025.0001.
Nandy A, et al. Gastroenterology. 2025;doi:10.1053/j.gastro.2025.01.247
Tanaka T, et al. JAMA Netw Open. 2025;doi:10.1001/jamanetworkopen.2025.1759.
In this edition, recurrence-free survival estimates in less advanced lung cancer, bronchoscopy-guided microwave ablation safe in lung abnormality and more.
Read the full coverage here:
Recurrence-free survival estimates after surgery higher in less advanced lung cancer
Electromagnetic navigation bronchoscopy-guided microwave ablation safe in lung abnormality
High prevalence of atherosclerosis detected in patients entering lung cancer therapy
Wood dust exposure negatively impacts lung function in carpenters
40% of people treated with chemotherapy develop persistent, severe nerve pain
References:
D'Souza RS, et al. Reg Anesth Pain Med. 2025;doi:10.1136/rapm-2024-106229.
Elfatih NM, et al. BMC Pulm Med. 2025;doi:10.1186/s12890-025-03535-x.
Malozzi C. Implementation science (application of research into practice/policy). Presented at: American College of Cardiology’s Advancing the Cardiovascular Care of the Oncology Patient course; Feb. 14-16, 2025; Washington, D.C.
Rajaram R, et al. CHEST. 2023;doi:10.1016/j.chest.2023.11.042.
Wang S, et al. J Thorac Dis. 2024;doi:10.21037/jtd-24-1052.
In this edition, robotic-assisted bronchoscopy a ‘game changer’, global mortality related to tobacco drops, particulate matter rises and more.
Read the full coverage here:
Robotic-assisted bronchoscopy a ‘game changer’ in early diagnosis of lung cancer
Global lung cancer mortality related to tobacco drops, particulate matter rises in 2019
Osimertinib linked to more therapy-related cardiac events than other TKIs for NSCLC
Survival better with lobectomy vs. wedge resection in early stage lung cancer
Zenocutuzumab exhibits efficacy in NRG1 fusion-positive cancers
References:
Expert Submission
Jani CT, et al. eClinicalMedicine. 2025;doi:10.1016/j.eclinm.2024.103033.
Lin CY, et al. JAMA Netw Open. 2024;doi:10.1001/jamanetworkopen.2024.48364.
Schram AM, et al. N Engl J Med. 2025;doi:10.1056/NEJMoa2405008.
Seder C. Anatomic lung resection is associated with improved survival compared with wedge resection for stage IA non-small cell lung cancer. Presented at: 2025 Society of Thoracic Surgeons Annual Meeting; Jan. 24-26; Los Angeles.
In this edition, combination extends survival vs. standard first-line therapy, integrated care for smoking cessation during lung cancer screening and more. Read the full coverage here:
Combination extends survival vs. standard first-line therapy for advanced lung cancer
Integrated care ‘best treatment option’ for smoking cessation during lung cancer screening
FDA proposes cap on nicotine levels in cigarettes
Global lifetime risk for lung cancer in 2022 differs by human development index, sex
FDA grants priority review to oral non-small cell lung cancer drug
References:
Cinciripini P, et al. JAMA Intern Med. 2024;doi:10.1001/jamainternmed.2024.7288.
Li M, et al. Chin Med J (Engl). 2024;doi:10.1097/CM9.0000000000003368.
Press Release
Press Release
Press Release
In this edition, we bring you Healio’s top lung cancer headlines in 2024.
Read the full coverage here:
California doctor with lung cancer receives first-of-its-kind lung-liver transplant
‘We were shocked’: Vaping considerably increases lung cancer risk among people who smoke
FDA places hold on trial of cell therapy for lung cancer after patient death
Findings highlight ‘desperate need’ to improve end-of-life cancer treatment
‘We have the technology’: Telehealth increases access to palliative care for cancer
References:
Canavan ME, et al. JAMA Oncol. 2024;doi:10.1001/jamaoncol.2024.1129.
Greer JA, et al. Abstract LBA3. Presented at: ASCO Annual Meeting; May 31-June 4, 2024: Chicago.
Healio Interviews
Press Release
Press Release
In this edition, single-fraction SBRT outcomes for central lung tumors, adjuvant durvalumab extends survival in limited-stage small cell lung cancer and more. Read the full coverage here:
Single-fraction SBRT confers ‘surprisingly excellent’ outcomes for central lung tumors
Adjuvant durvalumab extends survival in limited-stage small cell lung cancer
Depression among people with head and neck cancers likely underreported, undertreated
FDA approves tumor treating fields as part of combination therapy for advanced lung cancer
First-line maintenance regimen improves OS, PFS in extensive-stage small cell lung cancer
References:
Cheng Y, et al. Abstract LBA81. Presented at: European Society for Medical Oncology Congress; Sept. 13-17, 2024; Barcelona, Spain.
Malik NK, et al. Abstract 285. Presented at: ASTRO Annual Meeting; Sept. 29-Oct. 2, 2024; Washington, D.C.
Martinez MC, et al. JAMA Otolaryngol Head Neck Surg. 2024;doi:10.1001/jamaoto.2024.3233.
Press Release
Press Release
In this edition, FDA approves Rybrevant for advanced lung cancer, screening orders in eligible patients higher with digital health program and more. Read the full coverage here:
FDA approves Rybrevant for advanced lung cancer
Lung cancer screening orders in eligible patients higher with digital health program
FDA approves Opdivo regimen for resectable NSCLC
Study quantifies survival benefit of immunotherapy in metastatic NSCLC
FDA expands osimertinib approval for advanced non-small cell lung cancer
References:
Miller DP, et al. A direct-to-patient digital health program increases lung cancer screening: A pragmatic randomized controlled trial of mPATH-Lung. Presented at: CHEST Annual Meeting; Oct. 6-9, 2024; Boston.
Press Release
Press Release
Press Release
Ward Y, et al. Cancer. 2024;doi:10.1002/cncr.35476.
In this edition, blue-collar workers more likely to miss work or quit due to psoriatic arthritis, infliximab biosimilar increase after release of a third option and more. Read the full coverage here:
Blue-collar workers more likely to miss work, quit due to psoriatic arthritis
Infliximab biosimilar uptake rapidly increased only after release of a third option
National Psoriasis Foundation to honor leaders at 2025 Commit to Cure Gala
Safety checklist compiles clinically important DMARD warnings in one place
Guselkumab demonstrates long-term efficacy, safety in psoriasis
References:
Colla N, et al. Clin Rheumatol. 2024;doi:10.1007/s10067-024-07077-1.
Gargiulo L, et al. J Drugs Dermatol. 2024;doi:10.36849/JDD.7486R1.
Press Release
Roberts ET, et al. Arthritis Rheumatol. 2024;doi:10.1002/art.42963.
Skaarup L, et al. Drug Saf. 2024;doi:10.1007/s40264-024-01461-1.
In this edition, FDA approves first subcutaneous anti-PD-L1 cancer immunotherapy, ivonescimab ‘may be a new standard’ and more. Read the full coverage here:
FDA approves first subcutaneous anti-PD-L1 cancer immunotherapy
Ivonescimab extends PFS vs. pembrolizumab in advanced NSCLC, may be ‘a new standard’
Perioperative nivolumab improves outcomes in resectable NSCLC
Despite progress, barriers to lung cancer biomarker testing persist
Atezolizumab regimen ‘merits further study’ for unresectable NSCLC
References:
Forde PM, et al. Abstract 3589. Presented at: IASLC World Conference on Lung Cancer; Sept. 7-10, 2024; San Diego.
Press Release
Ross HJ, et al. JAMA Oncol. 2024;doi:10.1001/jamaoncol.2024.1897.
Smeltzer M, et al. Abstract 3000. Presented at: IASLC World Conference on Lung Cancer; Sept. 7-10, 2024; San Diego.
Zhou C, et al. Abstract 2700. Presented at: IASLC World Conference on Lung Cancer; Sept. 7-10, 2024; San Diego.
In this edition, FDA approves first subcutaneous anti-PD-L1 cancer immunotherapy, Ivonescimab ‘may be a new standard’ and more. Read the full coverage here:
FDA approves first subcutaneous anti-PD-L1 cancer immunotherapy
Ivonescimab extends PFS vs. pembrolizumab in advanced NSCLC, may be ‘a new standard’
Perioperative nivolumab improves outcomes in resectable NSCLC
Despite progress, barriers to lung cancer biomarker testing persist
Atezolizumab regimen ‘merits further study’ for unresectable NSCLC
References:
Forde PM, et al. Abstract 3589. Presented at: IASLC World Conference on Lung Cancer; Sept. 7-10, 2024; San Diego.
Press Release
Ross HJ, et al. JAMA Oncol. 2024;doi:10.1001/jamaoncol.2024.1897.
Smeltzer M, et al. Abstract 3000. Presented at: IASLC World Conference on Lung Cancer; Sept. 7-10, 2024; San Diego.
Zhou C, et al. Abstract 2700. Presented at: IASLC World Conference on Lung Cancer; Sept. 7-10, 2024; San Diego.
In this edition, enrollment and dosing complete in phase 1 trial of AIV007, popular benchmarks in clinical practice guidelines and more. Read the full coverage here:
Enrollment, dosing complete in phase 1 trial of AIV007 for AMD, diabetic macular edema
OCT, visual acuity popular benchmarks in clinical practice guidelines for DME
First patient dosed in phase 2 trial of EC-104 implant for diabetic macular edema
OCS-01 eye drop for DME in second stage of phase 3 trial
Q&A: Susvimo delivers immediate durability after implantation in wet AMD
References:
Crawford C. Update on OCS-01: A novel topical drop for DME in phase 3 trials. Presented at: Clinical Trials at the Summit; June 8, 2024; Park City, Utah.
Healio Interviews
McAllister M, et al. Assessing the strength of clinical practice guidelines for managing diabetic macular edema — A systematic literature review. Presented at: American Society of Retina Specialists annual meeting; July 17-20, 2024; Stockholm.
Press Release
Press Release
In this edition, drug discounts through Medicare price negotiations, opioid use has fallen 15% annually since 2014 and more. Read the full coverage here:
Enbrel, Stelara to be discounted nearly 70% through Medicare price negotiations
Opioid use has fallen 15% annually since 2014 in autoimmune rheumatic disease
Inhibitor class PsO treatments exhibit similar efficacy in mitigating PsA risk
S100 protein levels predict abatacept response in juvenile idiopathic arthritis
Izokibep shows early promise in hidradenitis suppurativa
References:
Brunner HI, et al. Arthritis Res Ther. 2024;doi:10.1186/s13075-024-03347-0.
Falasinnu T, et al. Lancet Rheumatol. 2024;doi:10.1016/S2665-9913(24)00120-6.
Press Release
Press Release
Tsai SHL, et al. J Am Acad Dermatol. 2024;doi:10.1016/j.jaad.2024.07.1473.
In this edition, low education level raises follow-up risk in screening program, screening judgement strongly influenced by clinicians and more. Read the full coverage here:
Low education level raises risk for loss to follow-up in lung cancer screening program
Lung cancer screening judgement strongly influenced by clinicians
Occupational benzene exposure heightens lung cancer likelihood
Chemotherapy plus nintedanib has ‘promising’ efficacy in small cell lung cancer with IPF
Blood biomarker identifying benign lung nodules performs well across subgroups
References:
Ikeda S, et al. Ann Am Thorac Soc. 2024;doi:10.1513/AnnalsATS.202311-941OC.
Long KJ, et al. CHEST. 2023;doi:10.1016/j.chest.2023.06.037.
Mugutso E, et al. Ann Am Thorac Soc. 2023;doi:10.1513/AnnalsATS.202304-348RL.
Núñez ER, et al. Am J Respir Crit Care Med. 2024;doi:10.1164/rccm.202301-0155OC.
Wan W, et al. Am J Respir Crit Care Med. 2024;doi:10.1164/rccm.202306-0942OC.
In this edition, sozinibercept combination therapy shows durability, comparable improvements with aflibercept and more. Read the full coverage here:
Sozinibercept combination therapy shows durability in patients with DME, neovascular AMD
VIDEO: Comparable improvements seen with aflibercept 8 mg vs. 2 mg in DME
DPP-IV, SGLT2 and GLP-1 drugs do not increase risk for diabetic macular edema
Eluminex doses first patient in phase 1b trial of EB-105 for diabetic macular edema
VIDEO: Port delivery system maintains visual, anatomic improvements in DME at 2 years
References:
Awh C. Port delivery system with ranibizumab for continuous treatment of diabetic macular edema: First readout of the phase 3 Pagoda trial year 2 results. Presented at: American Society of Retina Specialists annual meeting; July 17-20, 2024; Stockholm.
Do D. Outcomes of patients with DME and baseline BCVA of 20/50 or worse or 20/40 or better treated with aflibercept 8 mg and 2 mg in the phase 2/3 PHOTON trial. Presented at: American Society of Retina Specialists annual meeting; July 17-20, 2024; Stockholm.
Phu A, et al. J Diabetes Complications. 2024;doi:10.1016/j.jdiacomp.2024.108808.
Press Release
Steinle NC. Durability of combination therapy of sozinibercept (OPT-302), an anti-VEGF-C/-D ‘trap’ with ranibizumab in nAMD or aflibercept in DME. Presented at: American Society of Retina Specialists annual meeting; July 17-20, 2024; Stockholm.
In this edition, guselkumab brings ‘stringent’ control through 2 years, SARDs outpatient visits result in opioid prescriptions and more. Read the full coverage here:
Guselkumab brings active psoriatic arthritis into ‘stringent’ control through 2 years
Nearly one-quarter of all SARDs outpatient visits in US result in opioid prescription
FDA approves biosimilar Pyzchiva for all approved Stelara indications
Tofacitinib effective for juvenile idiopathic arthritis through 4 years
Bimekizumab results in rapid, sustained improvements to PsA patient reported outcomes
References:
Brunner HI, et al. Ann Rheum Dis. 2024;doi:10.1136/ard-2023-225094.
Gossec L, et al. Rheumatology. 2024;doi:10.1093/rheumatology/keae277.
Huang Y, et al. Arthritis Care Res. 2024;doi:10.1002/acr.25378.
Press Release
Ritchlin CT, et al. Clin Rheumatol. 2024;doi:10.1007/s10067-024-06991-8.
In this edition, atezolizumab benefits PD-L1-selected patients with NSCLC, risks persist with e-cigarette use after quitting tobacco smoking and more. Read the full coverage here:
Adjuvant atezolizumab benefits PD-L1-selected patients with NSCLC
Lung cancer risks persist with e-cigarette use after quitting tobacco smoking
COPD, IPF end of life health care use differs from lung cancer
Tecentriq combination fails to improve survival in metastatic lung cancer
Risk for lung cancer reoccurrence may be associated with OSA-related hypoxemia
References:
Figueroa Rodriguez F, et al. 0468: CRASH: Cancer reoccurrence is accelerated by episodic hypoxemia. Presented at: SLEEP; June 1-5, 2024; Houston.
Kim Y, et al. Association of electronic cigarette use after conventional smoking cessation with lung cancer risk: A nationwide cohort study. Presented at: American Thoracic Society International Conference; May 18-22, 2024; San Diego.
Press Release
Suen AO, et al. Am J Respir Crit Care Med. 2024;doi:10.1154/ajrccm-conference.2024.209.1_MeetingAbstracts.A5040.
Wakelee HA, et al. Abstract LBA8035. Presented at: ASCO Annual Meeting; May 31-June 4, 2024; Chicago.
In this edition, FDA approves Vabysmo prefilled syringe for retinal diseases, 4D Molecular Therapeutics updates on retinal disease candidates and more. Read the full coverage here:
FDA approves Vabysmo prefilled syringe for retinal diseases
VIDEO: 4D Molecular Therapeutics shares update on retinal disease candidates
FDA approves Eylea biosimilar FYB203/Ahzantive
VIDEO: Oral therapy improves central subfield thickness in DME in early-stage study
ANI Pharmaceuticals to acquire Alimera Sciences
References:
Agrawal R. RZ402: Initial results from a phase 2 study of a novel, orally administered PKal inhibitor in patients with DME. Presented at: Clinical Trials at the Summit; June 8, 2024; Park City, Utah.
Healio Interviews
Press Release
Press Release
Press Release
In this edition, extensive psoriasis and IBD history predict difficult-to-treat psoriatic arthritis, targeted therapies demonstrate low risk for serious infection and more. Read the full coverage here:
Extensive psoriasis, IBD history predict difficult-to-treat psoriatic arthritis
Targeted psoriatic arthritis therapies demonstrate low risk for serious infection
VIDEO: Dermatologists, rheumatologists share care in psoriasis, psoriatic arthritis
Patients with arthritis at higher risk for poor nutrition regardless of function
FDA approves Rinvoq for JIA, psoriatic arthritis in children aged 2 years and older
References:
Bastard L, et al. RMD Open. 2024;doi:10.1136/rmdopen-2023-003865.
Bennett R, et al. Sci Rep. 2024;doi:10.1038/s41598-024-58370-7.
Husni ME. Update in the treatment of psoriatic arthritis. Presented at: Medical Dermatology Therapy Update III; May 29-31, 2024; Cleveland.
Press Release
Vassilakis KD, et al. Rheumatology. 2024;doi:10.1093/rheumatology/keae263.
In this edition, screening program identifies airways disease in previously undiagnosed COPD, positive results show benefits of subcutaneous bispecifics and more. Read the full coverage here:
Lung cancer screening program identifies airways disease in previously undiagnosed COPD
Positive results in lung cancer show benefits of subcutaneous bispecifics
Adagrasib delays progression of pretreated KRAS-mutant lung cancer
Durvalumab extends survival in limited-stage small-cell lung cancer
Osimertinib delays progression ‘way more’ than hoped in EGFR-mutant lung cancer
References:
Bernstein E, et al. JCO Precis Oncol. 2024;doi:10.1200/po.23.00447.
Leighl NB, et al. Abstract LBA8505. Presented at: ASCO Annual Meeting; May 30–June 3, 2024; Chicago.
Ramalingam SS, et al. Abstract LBA4. Presented at: ASCO Annual Meeting; May 31-June 4, 2024: Chicago.
Seigo MA, et al. Pulmonary comorbidities, respiratory symptoms, and spirometry in a real-world, urban lung cancer screening program. Presented at: American Thoracic Society International Conference; May 17-22, 2024; San Diego.
Spigel DR, et al. Abstract LBA3. Presented at: ASCO Annual Meeting; May 31-June 4, 2024: Chicago.
In this edition, AI model helps predict anti-VEGF response in DME, Merck to acquire EyeBio and more. Read the full coverage here:
VIDEO: AI model helps predict anti-VEGF response in diabetic macular edema
Merck to acquire EyeBio
VIDEO: IOP remains stable up to 48 weeks with aflibercept 8 mg for DME
Phase 2 study of potential DME oral therapy meets primary endpoints
FDA approves aflibercept biosimilars Yesafili, Opuviz
References:
Barakat MR. Intraocular pressure outcomes with intravitreal injection of aflibercept 8 mg and 2 mg in patients with diabetic macular edema through week 48 of the phase 2/3 PHOTON trial. Presented at: Association for Research in Vision and Ophthalmology meeting; May 5-9, 2024; Seattle.
Luvisi J. Using a convolutional neural network to predict response of diabetic macular edema to intravitreal anti-vascular endothelial growth factor. Presented at: Kiawah Eye; May 30-June 1, 2024; Kiawah Island, South Carolina.
Press Release
Press Release
Press Release
In this edition, difficult-to-treat psoriatic arthritis 'not all about the therapies', Samsung biosimilar comparable to etanercept and more. Read the full coverage here:
Difficult-to-treat psoriatic arthritis 'not all about the therapies'
Samsung biosimilar comparable to etanercept for psoriatic arthritis outcomes at 1 year
Boehringer Ingelheim, Quallent partner to expand Humira biosimilar access
VIDEO: Mitigating risk for psoriatic arthritis in patients with psoriasis
FDA approves high-concentration, citrate-free form of interchangeable biosimilar Cyltezo
References:
Healio Interview
Łosińska K, et al. Arthritis Care Res. 2024;doi:10.1002/acr.25345.
Ogdie-Beatty A. Psoriatic Arthritis in 2024. Presented at The Congress of Clinical Rheumatology East; May 9-12, 2024; Destin, Florida (hybrid meeting).
Press Release
Press Release
In this edition, smoking cessation support uptake at lung cancer screenings, glecirasib may deliver ‘efficacy and tolerability advantages’ and more. Read the full coverage here:
Uptake of smoking cessation support high when offered at lung cancer screening
Glecirasib may deliver ‘efficacy and tolerability advantages’ for KRAS-mutant lung cancer
‘Substantial geographic disparities’ worsening in cancer clinical trial availability
Deployed military personnel have increased silica in lung tissue
FDA approves Alecensa for certain patients with ALK-positive lung cancer
References:
Lowers H, et al. Int J Environ Res Public Health. 2024;doi:10.3390/ijerph21010091.Press Release
Murray RL, et al. Eur Respir J. 2024;doi:10.1183/13993003.01768-2023.
Press Release
Sekar RR, et al. JAMA Netw Open. 2024;doi:10.1001/jamanetworkopen.2024.10162.
Shi Y, et al. Abstract 468214. Presented at: ASCO Plenary Series; April 30, 2024.
In this edition, FDA accepts new drug application for Eluminex, most mentors in vitreoretinal subspecialty are men and more. Read the full coverage here:
FDA accepts investigational new drug application for Eluminex DME treatment
Most mentors in vitreoretinal subspecialty are men
Carotid artery stenosis linked to retinal changes in patients with diabetic retinopathy
AI-assisted technology makes retinal imaging 100 times faster, with greater contrast
FDA clears fully autonomous AI for portable diabetic retinopathy screening
References:
Das V, et al. Commun Med. 2024;doi:10.1038/s43856-024-00483-1.
Lee CY, et al. BMC Ophthalmol. 2024;doi:10.1186/s12886-024-03391-z.
Press Release
Press Release
Shah SM, et al. Demographics and productivity trends among academically affiliated female vitreoretinal specialists in the United States. Presented at: Real World Ophthalmology; April 27, 2024 (virtual meeting).
In this edition, FDA approves Selarsdi as Stelara biosimilar, deucravacitinib improves ‘broad range’ of patient-reported outcomes and more. Read the full coverage here:
FDA approves Selarsdi as Stelara biosimilar for psoriasis, psoriatic arthritis
Deucravacitinib improves ‘broad range’ of patient-reported psoriatic arthritis outcomes
Advanced therapy not enough for nearly 75% of Canadian patients with psoriatic arthritis
New EULAR recommendations for psoriatic arthritis urge biologics after methotrexate failure
Dactylitis, enthesitis resolution linked to less pain, fatigue in guselkumab-treated PsA
References:
Gladman DD, et al. J Rheumatol. 2024;doi:10.3899/jrheum.2023-0716.
Gossec L, et al. Ann Rheum Dis. 2024;doi:10.1136/ard-2024-225531.
Press Release
Rahman P, et al. Clin Rheumatol. 2024;doi:10.1007/s10067-024-06921-8.
Strand V, et al. Arthritis Care Res. 2024;doi:10.1002/acr.25333.
In this edition, durvalumab improves survival in limited-stage small cell lung cancer, most adults do not test homes for radon exposure and more. Read the full coverage here:
Durvalumab improves survival in limited-stage small cell lung cancer
Survey: Most adults do not test homes for radon exposure, unconcerned about risks
FDA fast tracks investigational bispecific therapy for aggressive lung cancer
Research shows complexity of shared decision-making about lung cancer screening
Keytruda-Lynparza combination misses survival targets in phase 3 lung cancer trial
References:
Núñez E, et al. Ann Fam Med. 2024;doi:10.1370/afm.3081.
Press Release
Press Release.
Press Release
Press Release
In this edition, PALADIN study navigates IOP-lowering surgery in DME patients, small-molecule eye drop well-tolerated as treatment for retinal vascular diseases and more. Read the full coverage here:
PALADIN study: Navigating IOP-lowering surgery in DME patients for optimal outcomes
Small-molecule eye drop safe, well-tolerated as treatment for retinal vascular diseases
VIDEO: Reduction of vascular leakage, hyperreflective foci greater with faricimab
VIDEO: Real-world study shows durability of fluocinolone acetonide implant in DME
Early safety, efficacy results positive for Restoret in DME, wet AMD
References:
Chin Yee DS, et al. Outcomes in eyes requiring IOP-lowering surgery after treatment with the 0.19-mg fluocinolone acetonide implant for DME: The PALADIN study. Presented at: American Academy of Ophthalmology meeting; Nov. 3-6, 2023; San Francisco.
Graff JM. Biomarkers for vascular stability and inflammation demonstrate the benefit of dual Ang-2/VEGF-A inhibition with faricimab phase 3 trials in DME. Presented at: Retina 2024; Jan. 13-19, 2024; Wailea, Hawaii.
Minaker S. The 0.19mg fluocinolone acetonide (FAc) implant reduces the recurrence of edema by providing long-term control of retinal thickness variability in patients with DME: The 3-year PALADIN study. Presented at: Retina 2024; Jan. 13-19, 2024; Wailea, Hawaii.
Press Release
Press Release
In this edition, race identified as risk factor for VTE, FDA approves Rybrevant for treatment of non-small cell lung cancer and more. Read the full coverage here:
Race identified as risk factor for VTE after pulmonary resection for lung cancer
FDA approves Rybrevant for treatment of non-small cell lung cancer
Behavioral health disorders have a ‘big impact’ on cancer surgery outcomes
Optimizing immunotherapy, biomarker testing vital to progress in lung cancer treatment
FDA approves Tagrisso plus chemotherapy for EGFR-mutated non-small cell lung cancer
References:
Axtell AL, et al. Ann Thorac Surg. 2024;doi:10.1016/j.athoracsur.2024.01.005.
Katayama ES, et al. J Am Coll Surgeons. 2024;doi:10.1097/XCS.0000000000000954.
Press Release
Press Release
Press Release
In this edition, blood test for lung cancer patients who may benefit from further immunotherapy, invasive procedures following lung cancer screenings and more. Read the full coverage here:
Blood test identifies those with lung cancer who may benefit from further immunotherapy
Invasive procedures rarely follow false-positive lung cancer screenings
Study: Positive associations found between smoking and risk of ALS
Major cancer surgery associated with ‘elevated’ risk for venous thromboembolism
Quality improvement project bridges ‘significant gap’ in biomarker testing for lung cancer
References:
Anagnostou A, et al. Nat Med. 2023;doi:10.1038/s41591-023-02598-9.
Björklund J, et al. JAMA Netw Open. 2024;doi:10.1001/jamanetworkopen.2023.54352.
Healio Interviews
Kim YH, et al. Tob Induc Dis. 2024;doi:10.18332/tid/17531.
Manyak A, et al. CHEST. 2023;doi:10.1016/j.chest.2023.02.010.
In this edition, FDA places hold on cell therapy trial after patient death, selpercatinib delivers superior outcomes and more. Read the full coverage here:
FDA places hold on trial of cell therapy for lung cancer after patient death
Selpercatinib delivers superior outcomes, may ‘reduce the burden of NSCLC’
First-line immunotherapy benefits patients of all races with NSCLC equally
Never-smoker lung cancer survivors require targeted surveillance
Cemiplimab plus chemotherapy improves outcomes in metastatic NSCLC
References:
Baramidze A, et al. Abstract 1495P. Presented at: European Society for Medical Oncology Congress; Oct. 20-24, 2023; Madrid.
Choi E, et al. JAMA Netw. Open. 2023;doi:10.1001/jamanetworkopen.2023.43278.
Lee M, et al. J. Natl Compr Canc Netw. 2023;doi:10.6004/jnccn.2023.7064
Press Release
Zhou C, et al. N Engl J Med. 2023;doi:10.1056.NEJMoa2309457.
In this edition, an advocacy group petitions the FDA for stronger safety warnings for Botox, melanoma regression is associated with improved prognosis and more. Read the full coverage here:
Advocacy group petitions FDA for stronger safety warnings for Botox, related drugs
Melanoma regression associated with improved prognosis
Phase 4 results show Vtama cream efficacious in head, neck plaque psoriasis
Isotretinoin not associated with increased risk for suicide, psychiatric conditions
Tape strips may identify hidradenitis suppurativa in lesional, nonlesional skin
References:
Navrazhina K, et al. J Am Acad Dermatol. 2023;doi:10.1016/j.jaad.2023.11.048.
Press Release
Press Release
Tan NKW, et al. JAMA Dermatol. 2023;doi:10.1001/jamadermatol.2023.4579.
Wagner NB, et al. J Am Acad Dermatol. 2023;doi:10.1016/j.jaad.2023.11.040.
In this edition, allergic illnesses in children may be inherited from mothers; addressing needs of Muslim patients in dermatology; YouTube content on topical steroid withdrawal exhibits poor reliability and more. Read the full coverage here:
Atopic dermatitis, other allergic illnesses in children may be inherited from mothers
Addressing needs of Muslim patients in dermatology
YouTube content on topical steroid withdrawal exhibits poor reliability, quality
RelabotulinumtoxinA demonstrates rapid onset, durability for frown lines, crow’s feet
Puberty, skin of color, weight associated with acne prevalence among adolescents
References:
Chiesa Fuxench ZC, et al. J Am Acad Dermatol. 2023;doi:10.1016/j.jaad.2023.11.013.
El-Banna G, et al. JAMA Dermatol. 2023;doi:10.1001/jamadermatol.2023.4439.
McCormick E, et al. J Drugs Dermatol. 2023;doi:10.36849/JDD.C7443.
Press Release
Witkam WCAM, et al. J Am Acad Dermatol. 2023;doi:10.1016/j.jaad.2023.10.062.
In this edition, dermatologists ‘uniquely positioned’ to aid human trafficking victims; FDA approves Cosentyx for hidradenitis suppurativa and more. Read the full coverage here:
Dermatologists ‘uniquely positioned’ to recognize, aid human trafficking victims
FDA approves Cosentyx as first IL-17A inhibitor for hidradenitis suppurativa
FDA approves Stelara biosimilar for treatment of psoriasis, multiple inflammatory diseases
RECELL system efficacious in vitiligo repigmentation
Isotretinoin efficacious in seborrheic dermatitis treatment
References:
Elbuluk N. Optimizing melanocyte cell transplant procedure for treatment of vitiligo. Presented at: American Society for Dermatologic Surgery Annual Meeting; Nov 1-5, 2023; Chicago.
Kourosh S. The role of dermatologic surgeons in advocating for those affected by human trafficking. Presented at: American Society for Dermatologic Surgery Annual Meeting; Nov 1-5, 2023; Chicago.
Press Release
Press Release
Tan MG, et al. Isotretinoin for the management of moderate to severe seborrheic dermatitis. Presented at: American Society for Dermatologic Surgery Annual Meeting; Nov 1-5, 2023; Chicago.
In this edition, multicancer detection tests show promise; lifestyle counseling appointments benefit cancer survivors; use of low-value drugs for patients with cancer, and more.
Read the full coverage here:
Multicancer detection tests show promise, but questions linger about their accessibility
Shared medical appointments for lifestyle counseling benefit cancer survivors
Industry payments to physicians spur use of low-value drugs for patients with cancer
Study shows link between ultraprocessed foods and mortality risk
Radiation oncologist appointed to leadership role at NYU Langone’s Perlmutter Cancer Center
References:
Mitchell AP, et al. BMJ. 2023;doi:10.1136/bmj-2023-075512. Press Release Westgate C, Fischer J. What primary care physicians need to know about multicancer early detection tests. Presented at: OMED; Oct. 5-8, 2023. Winters LN. The development of an advanced practice nurse and registered dietician-led lifestyle medicine shared medical appointment program for cancer survivors. Presented at: Lifestyle Medicine 2023; Denver; Oct. 29-Nov. 1, 2023. Zhao Y, et al. Am J Prev Med. 2023;doi:10.1016/j.amepre.2023.09.005.
In this edition, FDA approves Bimzelx for plaque psoriasis; roflumilast foam improves quality of life in patients with seborrheic dermatitis and more. Read the full coverage here:
FDA approves Bimzelx for treatment of moderate to severe plaque psoriasis
Roflumilast foam improves quality of life in patients with seborrheic dermatitis
Opzelura effective, well tolerated in children aged at least 2 years with atopic dermatitis
Treatment for onychomycosis prescribed at only 20% of visits, impacting quality of life
Study: Important to weigh berdazimer gel benefits vs. risks in molluscum contagiosum
References:
Calvi IP, et al. Pediatr Dermatol. 2023;doi:10.1111/pde.15419.
Chu D. et al. Poster. Effect of roflumilast foam 0.3% on quality of life in patients with seborrheic dermatitis: patient-reported outcomes from the STRATUM phase III trial. Presented at: AMCP Nexus; Orlando.
Peck GM, et al. J Drugs Dermatol. 2023;doi:10.36849/JDD.6770.
Press Release
Press Release
In this edition, FDA issues complete response letter for relabotulinumtoxinA; mucocutaneous manifestations may signal COVID-induced inflammatory disease in children and more. Read the full coverage here:
FDA issues complete response letter for relabotulinumtoxinA for frown lines, crow’s feet
Mucocutaneous manifestations may signal COVID-induced inflammatory disease in children
FDA approves Zoryve for pediatric psoriasis
Colloidal oatmeal, prescription cream comparable in Black children with atopic dermatitis
FDA issues complete response letter for lebrikizumab for eczema treatment
References:
Imam B. Mucocutaneous clinical manifestation of multi-system inflammatory syndrome in children (MIS-C). Presented at: Skin of Color Update; Oct. 6-8, 2023; New York.
Lisante TA, et al. J Dermatolog Treat. 2023;doi:10.1080/09546634.2023.2241587.
Press Release
Press Release
Press Release
In this edition, precision navigators reduce racial disparities in genomic testing; cancer diagnoses fell sharply during early days of pandemic; Prostate Cancer Awareness Month updates, and more.
Read the full coverage here:
Precision navigators reduce racial disparities in genomic testing for prostate cancer
Cancer diagnoses fell sharply during early days of pandemic, NCI report shows
Prostate Cancer Awareness Month: Financial hardship common, exercise beneficial
Researchers identify 11 genes linked to aggressive prostate cancer
Black men less likely to receive targeted therapy for metastatic prostate cancer
References:
Allen AJ, et al. Abstract 122. Presented at: ASTRO Annual Meeting; Oct. 1-4, 2023; San Diego. Darst BF, et al. JAMA Oncol. 2023;doi:10.1001/jamaoncol.2023.3482. Healio Coverage Hwang C, et al. JAMA Netw Open. 2023;doi:10.1001/jamanetworkopen.2023.34208. Negoita S, et al. Cancer. 2023;doi:10.1002/cncr.35026.
In this edition, retinoids and OTC products for photoaged skin; fractional lasers show promise in skin cancer prevention; a botanical drug for severe thermal burns and more. Read the full coverage here: Prescription retinoids, OTC products positively impact photoaged skin
Fractional lasers show promise in skin cancer prevention
Botanical drug may outperform standard of care for treatment of severe thermal burns
5-fluorouracil cream noninferior to surgery for Bowen’s disease
Perifollicular linear projections aid in early diagnosis of facial lentigo maligna
References:
Ahmady S, et al. J Am Acad Dermatol. 2023;doi:10.1016/j.jaad.2023.08.076.
McCormick ET, et al. J Drugs Dermatol. 2023;doi:10.36849/JDD.2023.NVRN0923.
Navarrete-Dechent C, et al. J Am Acad Dermatol. 2023;doi:10.1016/j.jaad.2023.07.1036.
Press Release
Sadick N, et al. J Drugs Dermatol. 2023;doi:10.36849/JDD.7753.
In this edition, CDC issues a health advisory concerning flesh-eating bacterium, staging for melanoma does not represent accurate recurrence and mortality and more. Read the full coverage here:
CDC issues health advisory about recent reports of fatal Vibrio vulnificus
Study finds melanoma treatment costs have increased, but so has survival
Melanoma staging system inaccurately reflects recurrence, mortality risk
Study: Nemolizumab shows promise as prurigo nodularis treatment
Adverse events after ICI treatment linked to improved outcomes in patients with melanoma
References:
Bateni SB, et al. JAMA Dermatol. 2023;doi:10.1001/jamadermatol.2023.3179.
Deng J, et al. JAMA Dermatol. 2023;doi:10.1001/jamadermatol.2023.2609.
Du Y, et al. JAMA Dermatol. 2023;doi:10.1001/jamadermatol.2023.3003.
Helvind NM, et al. JAMA Dermatol. 2023;doi:10.1001/jamadermatol.2023.3256.
Press Release
In this edition, nearly $1 million in grants to aid diversity, equity, inclusion research; topical halcinonide may benefit patients with psoriasis; Asian patients may experience earlier mycosis fungoides diagnosis and more. Read the full coverage here:
Nearly $1 million in grants to aid dermatology research in diversity, equity, inclusion
Topical halcinonide may benefit patients with psoriasis with inadequate biologics response
Asian patients may experience earlier mycosis fungoides diagnosis, better outcomes
COVID-19 pandemic led to delayed melanoma diagnoses, more advanced tumors
Dupilumab use correlates with S. aureus reductions, atopic dermatitis improvements
References:
Bagel J, et al. J Drugs Dermatol. 2023;doi:10.36849/JDD.6830. Chen Z, et al. JAMA Dermatol. 2023;doi:10.1001/jamadermatol.2023.2634. Press Release Simpson EL, et al. J Allergy Clin Immunol. 2023;doi:10.1016/j.jaci.2023.05.026. Xiong D, et al. J Am Acad Dermatol. 2023;doi:10.1016/j.jaad.2023.08.040.
In this edition, ‘equitable access’ to care may reduce racial disparities in survival; exercise may improve sexual function among men with prostate cancer; image-guided adaptive prostate radiation therapy for short-term toxicities, and more.
Read the full coverage here:
‘Equitable access’ to care may reduce racial disparities in prostate cancer survival
Exercise may improve sexual function among men with prostate cancer
Image-guided adaptive prostate radiation therapy reduces risk for short-term toxicities
Recent developments in advanced prostate cancer space pave way for future breakthroughs
Radiation plus intensive systemic therapy improves outcomes in prostate cancer subset
References:
Bossi A, et al. Abstract LBA5000. Presented at: ASCO Annual Meeting; June 2-6, 2023; Chicago.
Galvao DA, et al. Abstract 71. Presented at: ASCO Breakthrough; Aug. 3-5, 2023; Yokohama.
Leeman JE, et al. Cancer.2023;doi:10.1002/cncr.34836.
Sayegh N, et al. JAMA Netw Open. 2023;doi:10.1001/jamanetworkopen.2023.26546.
Sharifi N, et al. J Clin Oncol. 2023;doi:10.1200/JCO.2022.40.16_suppl.5022.
In this edition, M-PDT efficacy similar to isotretinoin in acne vulgaris; Spitz neoplasm diagnosis in adults; immunotherapy treatment shows promise in basal cell carcinoma and more.
Read the full coverage here:
M-PDT efficacy similar to isotretinoin in acne vulgaris
Clinicians should not ‘shy away’ from a Spitz neoplasm diagnosis in adults
Novel nonsurgical immunotherapy treatment shows promise in basal cell carcinoma
Remibrutinib potential first-in-class oral treatment for chronic spontaneous urticaria
Clascoterone cream exhibits significant long-term improvement among children with acne
References:
Eichenfield LF, et al. J Drugs Dermatol. 2023;doi:10.36849/JDD.7592.
Hagstrom M, et al. J Am Acad Dermatol. 2023;doi:10.1016/j.jaad.2023.08.005.
Press Release
Press Release
Zhang L, et al. J Am Acad Dermatol. 2023;doi:10.1016/j.jaad.2023.07.1023.
In this edition, nonalcoholic muscadine wine may improve aging skin; atopic disease risk increases in sexually diverse patients; AI doubles diagnostic accuracy among patients with skin of color and more.
Read the full coverage here:
Nonalcoholic muscadine wine may improve aging skin in older women
Atopic disease risk increases in sexually diverse patients
AI doubles diagnostic accuracy of skin conditions among patients with skin of color
Post-acne scarring should be treated as primary skin condition
Histologic margin status can help predict lentigo maligna melanoma recurrence
References:
Christman L. Dealcoholized muscadine wine improved skin health, reduced oxidative stress and inflammation in women in a randomized controlled trial. Presented at: NUTRITION; July 22-25, 2023; Boston.
Hoang MP, et al. J Am Acad Dermatol. 2023;doi:10.1016/j.jaad.2023.07.008.
Rypka KJ, A, et al. JAMA Dermatol. 2023;doi:10.1001/jamadermatol.2023.1934.
Schneider JG, et al. J Drugs Dermatol. 2023;doi:10.36849/JDD.7581.
Zhou C, et al. Clin Cosmet Investig Dermatol. 2023;doi:10.2147/CCID.S406235.
In this edition, FDA approves Vanflyta for newly diagnosed ALL; liso-cel could have ‘best shot’ at remission for double refractory CLL; mortality factors among cancer survivors and more.
Read the full coverage here:
FDA approves Vanflyta for newly diagnosed acute myeloid leukemia
VIDEO: Liso-cel could have ‘best shot’ at remission for double refractory CLL
Community affluence, insurance mediate CV mortality among Black, white cancer survivors
VIDEO: MOLTO study probes combination therapy in Richter syndrome
Gilead terminates phase 3 trial of magrolimab regimen for myelodysplastic syndrome
References:
ASCO Annual Meeting
ASCO Annual Meeting
Press Release
Press Release
Sung H, et al. Int J Epidemiol. 2023;doi:10.1093/ije/dyad097.
In this edition, lack of sunless tanner education may cause confusion; intralesional HPV vaccine may clear recalcitrant warts; Ilumetri improves well-being of patients with plaque psoriasis and more.
Read the full coverage here:
Lack of sunless tanner education may cause diagnostic confusion, UV exposure
Intralesional HPV vaccine may clear recalcitrant warts
New, positive results show Ilumetri improves well-being of patients with plaque psoriasis
AB-101a rapidly reduces itch in patients aged as young as 2 years with atopic dermatitis
TikTok ‘excellent opportunity’ for dermatologists to create skin of color content
References:
Campbell JR, et al. J Drugs Dermatol. 2023;doi:10.36849/JDD.7061.
Hatch J, et al. Poster. Sunless tanners: An analysis of most common ingredients. Presented at: American Academy of Dermatology Annual Meeting; March 17-21, 2023; New Orleans.
Nofal A, et al. J Am Acad Dermatol. 2023;doi:10.1016/j.jaad.2023.06.042.
Press Release
Spelman L, et al. Phase 2 trial of novel topical drug candidate AB-101a for treatment of mild to moderate atopic dermatitis in children and adults. Presented at: 25th World Congress of Dermatology; July 3-8, 2023; Singapore.
In this edition, obesity linked to adverse outcomes among AYAs; pirtobrutinib produces high response rates; CDC study reveals overall increase in pediatric cancer incidence and more.
Read the full coverage here:
Overweight, obesity linked to adverse outcomes among AYAs treated for leukemia
Pirtobrutinib produces high response rates in heavily pretreated CLL, SLL
CDC study reveals overall increase in pediatric cancer incidence over 16 years
Cancers with high incidence among racial/ethnic minorities receive less research funding
Women more likely to experience severe toxicity from cancer treatment
References:
Haghighat S, et al. J Natl Cancer Inst. 2023;doi:10.1093/jnci/djad097.
Mato AR, et al. N Engl J Med. 2023;doi:10.1056/NEJMoa2300696.
Shimony S, et al. Blood Adv. 2023;doi:10.1182/bloodadvances.2023009976.
Siegel DA, et al. J Natl Cancer Inst. 2023;doi:10.1093/jnci/djad115.
Unger JM, et al. Abstract SY43-03. Presented at American Association for Cancer Research Annual Meeting; April 14-19, 2023; Orlando.
In this edition, novel serum improves hair growth in androgenetic alopecia; cardiovascular disease linked to dermatological inflammatory diseases; sugary drinks may be associated with male pattern hair loss and more.
Read the full coverage here:
Novel serum improves hair growth in androgenetic alopecia with no side effects
Cardiovascular disease associated with four dermatological inflammatory diseases
Consumption of sugary drinks may be associated with male pattern hair loss
Researchers advocate for promotion of skin self-examination for early melanoma detection
Plaque psoriasis oral therapy moves to phase 3 trial, being tested in other conditions
References:
Ingrassia JP, et al. J Am Acad Dermatol. 2023;doi:10.1016/j.jaad.2023.05.098.
Pagan AD, et al. J Drugs Dermatol. 2023;doi:10.36849/JDD.7424.
Press Release
Rapaport J, et al. J Drugs Dermatol. 2023;doi:10.36849/JDD.7403.
Shi X, et al. Nutrients. 2023;doi:10.3390/nu15010214.
In this edition, CAR-T trial for leukemia paused after patient death; obesity may increase risk for blood cancer; new CAR T-cell therapies ‘waiting’ for patients with leukemia and more.
Read the full coverage here:
Seattle Children’s pauses trial of CAR-T for leukemia after patient death
Obesity may increase risk for blood cancer
VIDEO: New CAR T-cell therapies ‘waiting in the wings’ for patients with leukemia
VIDEO: Jaktinib shows promise in treatment of myelofibrosis
Venetoclax regimen not superior to standard therapy alone for older patients with CLL
References:
ASCO Annual Meeting
ASCO Annual Meeting
Pasupuleti SK, et al. J Clin Invest. 2023;doi:10.1172/JCI163968.
Press Release
Woyach JA, et al. Abstract 7500. Presented at: ASCO Annual Meeting 2023; June 2-6, 2023; Chicago.
In this edition, Leqembi shows benefits in early Alzheimer’s, sex before bed has more positive impact on sleep, clearer guidelines needed on melatonin use in children and more.
Read the full coverage here:
FDA committee says Leqembi shows benefits in early Alzheimer’s
Sex before bed has more positive impact on sleep vs. medication in adults with insomnia
Increased education, clearer guidelines needed on melatonin use in children
FDA approves Elevidys for pediatric Duchenne muscular dystrophy
CMS announces plan for Medicare coverage of approved Alzheimer's drugs
References:
Kirsch D, et al. How well does sexual activity improve sleep when compared with pharmacologic sleep aids? Presented at: SLEEP; June 3-7, 2023; Indianapolis.
Owens J. Navigating the challenges in talking to patients and families about melatonin. Presented at: SLEEP; June 3-7, 2023; Indianapolis.
Press Release
Press Release
Press Release
In this edition, prior authorization linked delay in prescription fills; disparities in access to specialized cancer centers; ‘new potential treatment option’ for advanced chronic lymphocytic leukemia and more.
Read the full coverage here:
Prior authorization policies linked to 2-week delay in anticancer-drug prescription fills
AYAs with rare leukemia face disparities in access to specialized cancer centers
Liso-cel CAR-T ‘new potential treatment option’ for advanced chronic lymphocytic leukemia
Benefits of ivosidenib regimen for IDH1-mutant AML increase with longer follow-up
Childhood cancer survivors at increased risk for sleep concerns decades after diagnosis
References:
Daniel LC. Sleep in long-term childhood cancer survivors compared to siblings: A report from the Childhood Cancer Survivor Study. Presented at: SLEEP; June 3-7, 2023; Indianapolis.
De Botton S, et al. Abstract 7012. Presented at: ASCO Annual Meeting; June 2-6, 2023; Chicago.
Kyle MA, et al. Abstract 1504. Presented at: ASCO Annual Meeting; June 2-6, 2023; Chicago.
Muffly L, et al. Abstract 7008. Presented at: ASCO Annual Meeting; June 2-6, 2023; Chicago.
Siddiqi T, et al. Abstract 7501. Presented at: ASCO Annual Meeting; June 2-6, 2023; Chicago.
In this edition, surgery confers higher 5-year survival rates than radiotherapy; first-line combination extends PFS in lung cancer subgroup; pembrolizumab improves outcomes in early-stage resectable lung cancer, and more.
Read the full coverage here:
Surgery confers higher 5-year survival rates than radiotherapy in early-stage lung cancer
First-line combination extends PFS in lung cancer subgroup
Pembrolizumab improves outcomes in early-stage resectable lung cancer
Chemotherapy after first-line EGFR TKI fails to extend survival in advanced NSCLC
Severe myelosuppression common after chemotherapy for small cell lung cancer
References:
Hart L, et al. Cancer Med. 2023;doi:10.1002/cam4.5738.
Kanda S, et al. Abstract LBA9009. Presented at: ASCO Annual Meeting; June 2-6, 2023; Chicago.
Press Release
Udelsman B, et al. Abstract 275. Presented at: American Association for Thoracic Surgery Annual Meeting; May 6-9, 2023; Los Angeles.
Wakelee H, et al. Abstract LBA100. Presented at: ASCO Annual Meeting; June 2-6, 2023; Chicago.
In this edition, cross-border partnership takes on survival gap for children with leukemia; ‘paradigm shift’ in transfusion-dependent myelodysplastic syndrome; FDA approves Ayvakit for mastocytosis and more. Read the full coverage here:
Cross-border partnership takes on ‘huge survival gap’ among children with leukemia
Luspatercept ‘a paradigm shift’ in transfusion-dependent myelodysplastic syndrome
FDA approves Ayvakit for indolent systemic mastocytosis
Novel leukemia treatment signals ‘new era in CAR T-cell therapy’
Functional precision medicine-guided approach benefits pediatric patients with cancer
References:
Acanda de la Rocha AM, et al. Abstract LB358. Presented at: American Association of Cancer Research Annual Meeting; April 14-19, 2023; Orlando.
Appelbaum J, et al. Abstract 3092. Presented at: American Society of Gene & Cell Therapy Annual Meeting; May 16-20, 2023; Los Angeles.
Aristizabal P, et al. Abstract 1502. Presented at: ASCO Annual Meeting; June 2-6, 2022; Chicago.
Garcia-Manero G, et al. Abstract 7003. Scheduled for presentation at: ASCO Annual Meeting; June 2-6, 2022; Chicago.
Press Release
In this edition, FDA approves supplemental new drug application for Rexulti, early amyloid PET provides high diagnostic confidence, Leqembi reduced biomarkers of Alzheimer’s and more.
Read the full coverage here:
FDA approves supplemental new drug application for Rexulti to treat Alzheimer's agitation
Early amyloid PET provides high diagnostic confidence for adults with cognitive impairment
Leqembi reduced biomarkers of Alzheimer’s, slowed cognitive decline at 18 months
FDA grants 510(k) clearance for self-directed EEG headset
Oral Bruton’s tyrosine kinase inhibitor reduced brain lesions in phase 2 MS trial
References:
Altomare D, et al. JAMA Neurol. 2023;doi:10.1001/jamaneurol.2023.0997.
Press Release
Press Release
Press Release
Van Dyck CH, et al. A study to confirm safety and efficacy of lecanemab in participants with early Alzheimer’s disease (Clarity AD). Presented at: American Academy of Neurology annual meeting; April 22-27, 2023; Boston.
In this edition, we bring you a deep dive on a collaboration that aims to accelerate better treatments for pediatric cancers. Read the full coverage here:
Collaboration aims to ‘truly accelerate better treatments’ for pediatric cancers
References:
Dharia NV, et al. Nat Med. 2021;doi:10.1038/s41588-021-00819-w.
In this edition, tumor mutational burden linked to immunotherapy response; toripalimab regimen extends EFS in stage III NSCLC; phase 3 study designed for increasing trial diversity, and more.
Read the full coverage here:
Tumor mutational burden may be linked to immunotherapy response in advanced cancers
Perioperative toripalimab regimen extends EFS in resectable stage III NSCLC
Phase 3 study of lung cancer regimen designed to be a model for increasing trial diversity
Smoking cessation before lung cancer diagnosis significantly reduces excess mortality risk
Pembrolizumab active in diffuse malignant peritoneal mesothelioma
References:
Aggarwal C, et al. JAMA Netw Open. 2023;doi:10.1001/jamanetworkopen.2023.11181.
Lu S, et al. Abstract 425126. Presented at: ASCO Plenary Series: April 2023 Session; April 20, 2023.
Marmarelis ME, et al. JAMA Netw Open. 2023;doi:10.1001/jamanetworkopen.2023.2526.
Pragmatica-Lung Study, a streamlined model for future cancer clinical trials, begins enrolling patients (NCI press release). Published April 12, 2023. Accessed April 12, 2023.
Wang X, et al. JAMA Netw Open. 2023;doi:10.1001/jamanetworkopen.2023.11966.
In this edition, immunotherapy improves survival rates of infants with leukemia; extreme poverty linked to higher risk for relapse among children with ALL; FDA approves allogeneic cell therapy and more. Read the full coverage here:
Addition of immunotherapy to chemotherapy improves survival rates of infants with leukemia
Extreme poverty linked to nearly twofold higher risk for relapse among children with ALL
FDA approves allogeneic cell therapy Omisirge for patients with blood cancers
Vaping linked to cancer-related cognitive impairment among young adult cancer survivors
Intervention reduces financial toxicity among people with blood cancers
References:
Healio Interview
Ng DQ, et al. JCO Oncol Pract. 2023;doi:10.1200/op.22.00458.
Press Release
van der Sluis IM, et al. N Eng J Med. 2023;doi:10.1056/NEJMoa2214171.
Wadhwa A, et al. Blood. 2023;doi:10.1182/blood.2023019631.
In this edition, trichloroethylene may be ‘invisible’ cause of PD, ravulizumab reduces clinical deterioration in generalized myasthenia gravis and more.
Read the full coverage here:
Trichloroethylene may be ‘invisible and highly preventable’ cause of Parkinson’s disease
DEA petitioned to de-schedule dual orexin receptor antagonist insomnia medications
Ravulizumab reduces clinical deterioration in patients with generalized myasthenia gravis
FDA places partial clinical hold on initiation of new patients in evobrutinib study
FDA advisory committees rule in favor of Rexulti for agitation associated with Alzheimer’s
References:
Dorsey ER, et al. J Parkinsons Dis. 2023;doi:10.3233?JPD-225047.
Mantegazza R, et al. Poster 148: Ravulizumab reduces clinical deteriorations in patients with generalized myasthenia gravis: Results from the CHAMPION MG study. Presented at: Muscular Dystrophy Association Clinical & Scientific Conference; March 19-22, 2023; Dallas.
Press Release
Press Release
Press Release
In this edition, elevated cardiotoxicity risk for Black patients after chemotherapy; CV risk factor disparities in childhood cancer survivors; neural network helps identify potential targets for cancer drugs and more. Read the full coverage here:
Black patients may be at elevated cardiotoxicity, HF risk after chemotherapy
CV risk factor disparities in childhood cancer survivors similar to general population
Neural network helps identify many more potential targets for cancer drugs
Blood or marrow transplant survivors at high risk for malignant neoplasms in the GI tract
Optimizing CV health behaviors may lower risk for CVD and cancer
References:
Gebeyehu W, et al. Original Research Abstract 56. Presented at: American College of Cardiology’s Advancing the Cardiovascular Care of the Oncology Patient conference; April 14-16, 2023; Washington, D.C. (hybrid meeting).
McDonald A, et al. JAMA Oncol. 2023;doi:10.1001/jamaoncol.2022.6569.
Meller A, et al. Nat Commun. 2023;doi:10.1038/s41467-023-36699-3.
Noyd DH, et al. JACC CardioOncol. 2023;doi:10.1016/j.jaccao.2023.01.011.
van Sloten T, et al. JACC CardioOncol. 2023;doi:10.1016/j.jaccao.2022.11.015.
In this edition, DNA sequencing could identify patients with high-risk AML; review of major advances and challenges in chronic lymphocytic leukemia; FDA advisory panel backs polatuzumab vedotin and more. Read the full coverage here:
DNA sequencing could identify patients with AML at high risk for relapse after HSCT
Review highlights major advances, continuing challenges in chronic lymphocytic leukemia
FDA advisory panel backs polatuzumab vedotin-piiq benefit-risk profile in first-line DLBCL
CAR T cells improve quality of life for majority of recipients
Community physicians play essential role in long-term care after CAR-T
References:
Dillon LW, et al. JAMA. 2023;doi:10.1001/jama.2023.1363.
Healio Interviews
Johnson PC, et al. Blood Adv. 2023;doi:10.1182/bloodadvances.2022009117.
March 9, 2023 meeting of the Oncologic Drugs Advisory Committee (ODAC). Available at: https://www.youtube.com/watch?v=zCf87ABhqpU. Accessed March 9, 2023.
Shadman M. JAMA. 2023;doi:10.1001/jama.2023.1946.
In this edition, ‘paradigm shift’ in non-small cell lung cancer during past decade; osimertinib extends survival in early EGFR-mutated NSCLC; amivantamab shows durable activity in patients with advanced NSCLC, and more.
Read the full coverage here:
Study reveals ‘paradigm shift’ in non-small cell lung cancer during past decade
Osimertinib extends survival in early EGFR-mutated non-small cell lung cancer
Amivantamab-vmjw shows durable activity in subgroup of patients with advanced NSCLC
Patients with small cell lung cancer have ‘real choice’ in radiotherapy regimen
Pembrolizumab regimen extends OS in advanced malignant pleural mesothelioma
References:
Bogart J, et al. J Clin Oncol. 2023;doi:10.1200/JCO.22.01359.
Chi SA, et al. JAMA Netw Open. 2023;doi:10.1001/jamanetworkopen.2023.2002.
Press Release
Press Release
Press Release
In this edition, optimal antibiotics timing among inpatients with cancer; inflammation levels linked to survival in acute myeloid leukemia; dexrazoxane confers long-term cardioprotection for pediatric cancer and more. Read the full coverage here:
Optimal antibiotics timing ‘likely differs’ among inpatients with cancer, neutropenic fever
Inflammation levels linked to survival in acute myeloid leukemia
Dexrazoxane confers long-term cardioprotection after anthracyclines for pediatric cancer
Menin inhibitor produces high response rates in certain acute leukemia subtypes
Tisa-cel CAR-T reinfusion lacks durability for younger patients with B-cell ALL
References:
Chow EJ, et al. J Clin Oncol. 2023;doi:10.1200/JCO.22.02423.
Issa GC, et al. Nature. 2023;doi:10.1038/s41586-023-05812-3.
Krupski C, et al. Abstract LBA4. Presented at: Tandem Meetings | Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR, Feb. 15-19, 2023; Orlando.
Lasry A, et al. Nat Cancer. 2022;doi:10.1038/s43018-022-00480-0. Villars J, et al. Am J Med Qual. 2023;doi:10.1097/JMQ.0000000000000093.
In this edition, FDA clears lab blood test for evaluating concussion, marriage linked to lower risk for dementia, FDA approves nasal spray for migraine in adults and more.
Read the full coverage here:
FDA clears lab blood test for evaluating concussion
Marriage linked to lower risk for dementia, mild cognitive impairment
FDA approves nasal spray for migraine in adults
Noninvasive device for treating tinnitus receives FDA de novo approval
Differences in fighter pilots’ brain connectivity may have implications for space travel
References:
Press Release
Press Release
Press Release
Radstake WE, et al. Front Physiol. 2023;doi:10.3389/fphys.2023.1082166.
Skirbekk V, et al. J Aging Health. 2023;doi:10.1177/08982643221131926.
In this edition, outpatient HSCT feasible for older adults; ponatinib for newly diagnosed Ph+ALL; iomab-B may increase transplant access in relapsed/refractory AML and more. Read the full coverage here:
Outpatient HSCT feasible for older adults with AML, myelodysplastic syndrome
Ponatinib ‘should be considered a standard of care’ for newly diagnosed Ph+ALL
Iomab-B may increase transplant access, improve outcomes in relapsed/refractory AML
Living along US-Mexico border linked to higher risk for death among children with leukemia
Breyanzi study meets complete response endpoint for leukemia, lymphoma subgroup
References:
Castellanos MI, et al. Cancer. 2023;doi:10.1002/cncr.34636.
Gyurkocza B, et al. Abstract LBA3. Presented at: Tandem Meetings | Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR, Feb. 15-19, 2023; Orlando.
Jabbour E, et al. Abstract 398868. Presented at: ASCO Plenary Series: February 2023 Session; Feb. 15, 2023.
Muffly L, et al. Abstract 86. Presented at: Tandem Meetings | Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR, Feb. 15-19, 2023; Orlando.
Press Release
In this edition, nivolumab confers durable survival benefit; global economic cost of cancer estimated to exceed $25 trillion; phase 3 trials of pembrolizumab miss primary endpoints, and more.
Read the full coverage here:
Neoadjuvant nivolumab confers durable survival benefit in resectable NSCLC
Global economic cost of cancer estimated to exceed $25 trillion over 30 years
Phase 3 trials of pembrolizumab in prostate, lung cancer miss primary endpoints
Researchers develop AI model to accelerate radiation therapy planning for lung cancer
Asian, Black patients with lung cancer face longer wait times to radiation treatment
References:
Chen S, et al. JAMA Oncol. 2023;doi:10.1001/jamaoncol.2022.7826.
Hosny A, et al. Lancet Digit Health. 2022;doi:10.1016/S2589-7500(22)00129-7.
Press Release
Rekulapelli A, et al. Health Equity. 2022;doi:10.1089/heq.2022.0104
Rosner S, et al. Clin Cancer Res. 2023;doi:10.1158/1078-0432.CCR-22-2994.
In this edition, novel T-cell therapy effective against common viruses; FDA approves Brukinsa for chronic lymphocytic leukemia; meeting abstracts show inconsistent toxicity reporting and more. Read the full coverage here:
Novel T-cell therapy effective against common viruses after stem cell transplantation
FDA approves Brukinsa for chronic lymphocytic leukemia, small lymphocytic lymphoma
Review of meeting abstracts shows toxicity reporting inconsistent, incomplete
Cumulative anesthesia exposure linked to impaired neurocognitive function in pediatric ALL
Imetelstat confers durable transfusion independence in lower-risk myelodysplastic syndrome
References:
Alexander S, et al. Abstract 901. Presented at: ASH Annual Meeting and Exposition; Dec. 10-13, 2022; New Orleans.
Chin-Yee B, et al. Abstract 129. Presented at: ASH Annual Meeting and Exposition; Dec. 10-13, 2013; New Orleans.
Pfeiffer T, et al. Clin Cancer Res. 2023;doi:10.1158/1078-0432.CCR-22-2415.
Press Release
Press Release
In this edition, lobectomy alternatives show adverse event profiles; frequent CT scans not linked to better surgery outcomes; FDA approves adjuvant Keytruda, and more. Read the full coverage here:
Lobectomy alternatives show varying adverse event profiles in early-stage lung cancer
More frequent CT scans not linked to better outcomes after lung cancer surgery
Osimertinib-related pneumonitis incidence higher in real-world lung cancer population
FDA approves adjuvant Keytruda for non-small cell lung cancer
Tarlatamab active in recurrent small cell lung cancer
References:
Heiden BT, et al. J Natl Cancer Inst. 2023;doi:10.1093/jnci/djac208.
Paz-Ares L, et al. J Clin Oncol. 2023;doi:10.1200/JCO.22.02823.
Press Release
Sato Y, et al. CHEST. 2022;doi:10.1016/j.chest.2022.05.035.
Wang Q, et al. Ann Am Thorac Soc. 2022;doi:10.1513/AnnalsATS.202203-275OC.
In this edition, addition of tumor treating fields extends OS; atezolizumab-bevacizumab survival rates; screening leads to more stage I, less stage IV disease incidence, and more.
Read the full coverage here:
Addition of tumor treating fields to standard therapy extends OS in advanced lung cancer
Atezolizumab-bevacizumab confers ‘much higher than usual’ survival rates in NSCLC subset
Lung cancer screening leads to more stage I, less stage IV disease incidence
Anti-TIGIT regimens improve outcomes vs. anti-PD-1 alone in lung cancer subgroup
FDA approves adagrasib for certain adults with non-small cell lung cancer
References:
Johnson ML, et al. Abstract 397600. Presented at: ASCO Plenary Series: December 2022 Session; Dec. 20, 2022.
Press Release
Press Release
Provencio M, et al. JAMA Oncol. 2022;doi:10.1001/jamaoncol.2022.5959.
Vachani A, et al. J Thorac Oncol. 2022;doi:10.1016/j.jtho.2022.08.011.
In this edition, groups support CMS policy update on colonoscopy; plant-based food intake and CRC research needed; FDA agrees on pediatric study to develop obefazimod and more.
Read the full coverage here:
Exact Sciences backs CMS policy update to waive cost-sharing for follow-up colonoscopy
Future research needed to investigate link between plant-based food intake, CRC
FDA agrees on Abivax’s pediatric study plan to develop obefazimod for children with IBD
Roux-en-Y tied to increased risk for hospitalization related to alcohol-use disorder
Robotic liver resection for HCC reduced length of hospital stay, ICU admissions
References:
Benedetto FD, et al. JAMA Surg. 2022;doi:10.1001/jamasurg.2022.5697.
Kim J, et al. BMC Medicine. 2022;doi:10.1186/s12916-022-02633-7.
Mahmud N, et al. JAMA Surg. 2022;doi:10.1001/jamasurg.2022.6410.
Press Release
Press Release
In this edition, NCI director announces breast cancer diagnosis, neoadjuvant chemotherapy regimen in pancreatic cancer, gender harassment is in oncology and more.
Read the full coverage here:
NCI director announces breast cancer diagnosis, says prognosis ‘very favorable’
Neoadjuvant chemotherapy regimen extends survival in pancreatic cancer
Survey shows gender harassment is ‘strikingly common’ in oncology
Proton pump inhibitor use linked to elevated cancer risk
Memorial Sloan Kettering pauses CAR-T clinical trial to investigate patient death
References:
Katz MHG, et al. JAMA Oncol. 2022;doi:10.1001/jamaoncol.2022.2319.
Press Release
Press Release
Subbiah IM, et al. J Clin Oncol. 2022;doi:10.1200/JCO.21.02574.
Tran TH, et al. Abstract 1843. Presented at: World Cancer Congress; Oct. 18-20, 2022; Geneva.
In this edition, cancer and COVID-19 increase risk for thromboembolism, glofitamab shows curative potential in lymphoma, efgartigimod improves platelet counts, and more.
Read the full coverage here:
Biomarkers predict thromboembolism risk, mortality among people with cancer, COVID-19
Glofitamab shows ‘curative potential’ in relapsed/refractory diffuse large B-cell lymphoma
Efgartigimod confers rapid improvement in platelet counts in immune thrombocytopenia
Odronextamab ‘potentially curative’ in third-line setting for follicular lymphoma
Dana-Farber professor receives William Dameshek Prize for multiple myeloma research
References:
Broome CM, et al. Abstract 3. Presented at: ASH Annual Meeting and Exposition; Dec. 10-13, 2022; New Orleans.
Hutchings M, et al. Abstract 441. Presented at: ASH Annual Meeting and Exposition; Dec. 10-13, 2022; New Orleans.
Khorana AA, et al. Abstract 136. Presented at: ASH Annual Meeting and Exposition; Dec. 10-13, 2022; New Orleans.
Kim TM, et al. Abstract 949. Presented at: ASH Annual Meeting and Exposition; Dec. 10-13, 2022; New Orleans.
Press Release
In this edition, alcohol consumption increases cancer risk, medical marijuana associated with lower rates of opioid prescriptions, lifelong stress increases risk for cancer mortality, and more.
Read the full coverage here:
Many Americans unaware of alcohol links to cancer risk
Medical marijuana ‘may be substituting for opioids for cancer-related pain’
Lifelong stress may increase risk for cancer mortality
FDA approves olutasidenib for certain adults with acute myeloid leukemia
Data support less aggressive approach before transplant in relapsed/refractory AML
References:
Bao Y, et al. JAMA Oncol. 2022;doi:10.1001/jamaoncol.2022.5623.
Moore JX, et al. SSM Popul Health. 2022;doi:10.1016/j.ssmph.2022.101185.
Press Release
Seidenberg AB, et al. Cancer Epidemiol Biomarkers Prev. 2022;doi:10.1158/1055-9965.EPI-22-0420.
Stelljes M, et al. Abstract 4. Presented at: ASH Annual Meeting and Exposition; Dec. 10-13, 2022; New Orleans.
In this episode, FDA grants fast track designation to REM-001; practice-changing treatment advances continue; proton partial breast radiotherapy appears effective and more.
Read the full coverage here:
FDA grants fast track designation to REM-001 for cutaneous metastatic breast cancer
Practice-changing treatment advances continue in early-stage triple-negative breast cancer
Proton partial breast radiotherapy appears effective, safe for early breast cancer
New endocrine therapy options for patients with breast cancer on the horizon, expert says
Use of contraception decreases after breast cancer diagnosis
References:
Choi JI, et al. Clin Transl Radiat Oncol. 2022;doi:10.1016/j.ctro.2022.08.013
Healio Interviews
Lambertini M, et al. JAMA Netw Open. 2022;doi:10.1001/jamanetowrkopen.2022.33137.
Press Release
Traina TA, et al. Early-stage triple-negative breast cancer. Presented at: 40th Annual Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow; Nov. 9-11, 2022.
In this edition, fludarabine has been placed on the FDA’s drug shortage list; epcoritamab is approved for advanced lymphoma; pembrolizumab with chemotherapy improves OS in gastric cancer, and more.
Read the full coverage here:
Fludarabine shortage requires flexibility, alternative approaches for CAR-T and HSCT
FDA grants priority review to epcoritamab for advanced lymphoma
Pembrolizumab regimen extends OS in metastatic gastric, gastroesophageal junction cancers
New endocrine therapy options for patients with breast cancer on the horizon, expert says
Treatment sequencing key as options increase for patients with urothelial cancer
References:
Petrylak DP. Sequencing therapy throughout the urothelial treatment continuum. Presented at: 40th Annual Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow; Nov. 9-11, 2022.
Press Release
Press Release
In this edition, foslevodopa-foscarbidopa improves motor symptoms in advanced PD, posterior surgery for treating cervical radiculopathy, Tysabri favored over IV in patients with relapsing-remitting MS and more.
Read the full coverage here:
Continuous subcutaneous foslevodopa-foscarbidopa improves motor symptoms in advanced PD
Posterior surgery noninferior to anterior for treating cervical radiculopathy
Subcutaneous delivery of Tysabri favored over IV in patients with relapsing-remitting MS
NeuroLogica receives FDA clearance for multiuse imaging tool
Vumerity effective over 96 weeks in patients with relapsing-remitting MS
References:
Broekema AEH, et al. JAMA Neurol. 2022;doi:10.1001/jamaneurol.2022.4208.
Gold R, et al. SISTER – subcutaneous: non-interventional, observational, prospective, German multicenter, open-label study over 12-months for Tysabri patient preference – experience from real world – preliminary results of the 1st interim analysis. Presented at: ECTRIMS 2022; Oct. 26-28; Amsterdam.
Press Release
Singer BA, et al. Diroximel fumarate in patients with relapsing-remitting multiple sclerosis: Final safety and efficacy results from the phase 3 EVOLVE-MS-1 study. Presented at: ECTRIMS 2022; Oct. 26-28; Amsterdam.
Soileau MJ, et al. Lancet Neurol. 2022;doi:10.1016/S1474-4422(22)00400-8.
In this edition, risk factors linked to PD, digital brain health platform offers dementia risk assessment, Klotho protein levels linked to Alzheimer's and more.
Read the full coverage here:
Tremor, restless legs syndrome, schizophrenia among risk factors linked to PD
Digital brain health platform offers rapid, accurate assessment of dementia risk
Klotho protein levels linked to Alzheimer's, cognitive decline, amyloid and tau burden
Body temperature irrigation for chronic subdural hematoma should be ‘standard of care’
FDA requests additional information, extends goal date for application of MS treatment
References:
Bartley A, et al. JAMA Neurol. 2022;doi:10.1001/jamaneurol.2022.4133.
Grøntvedt GR, et al. JAMA Netw Open. 2022;doi:10.1001/jamanetworkopen.2022.43232.
Press Conference
Press Release
Schrag A et al. JAMA Neurology. 2022;doi:10.1001/jamaneurol.2022.3902.
In this edition, disparities among women in the surgical workforce, GSK withdraws belantamab mafodotin from US market, risk for lymphoma low after postmastectomy reconstruction, and more.
Read the full coverage here:
More women surgeon scientists receive NIH funding than in 2010, yet gender gaps remain
GSK to withdraw multiple myeloma therapy from US market
Risk for lymphoma after postmastectomy breast implant reconstruction ‘still extremely low’
Differences observed in adverse events of antibody-drug conjugates
FDA approves Hemgenix as first gene therapy for treatment of hemophilia B
References:
Kinslow CJ, et al. JAMA Netw Open. 2022;doi:10.1001/jamanetworkopen.2022.43396.
Press Release
Press Release
Saif A, et al. JAMA Surg. 2022;doi:10.1001/jamasurg.2022.5157
Zhu Y, et al. Cancer. 2022;doi:10.1002/cncr.34507.
In this edition, lung cancer screening critically low across the U.S, first in-human CRISPR test with gene replacement, racial and economic segregation linked to higher cancer mortality rates, and more.
Read the full coverage here:
Lung cancer screening rates in US ‘simply unacceptable’
First CRISPR-based cell therapy to use gene replacement feasible, safe for solid tumors
Racial, economic segregation linked to cancer mortality
Onivyde regimen extends OS in metastatic pancreatic ductal adenocarcinoma
Immunotherapy a ‘significant improvement’ for treatment of multiple myeloma
References:
Davies FE, et al. New therapeutic agents for relapsed/refractory multiple myeloma: CAR T and bispecific antibodies. Presented at: 40th Annual Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow; Nov. 9-11, 2022.
Foy SP, et al. Abstract 1478. Presented at: Society for Immunotherapy of Cancer Annual Meeting; Nov. 8-12, 2022; Boston.
Press Release
Press Release
Zhang L, et al. JAMA Oncol. 2022;doi:10.1001/jamaoncol.2022.5382.
In this edition, best practice statements for celiac disease; older patients with IBD at risk for treatment failure with vedolizumab; Follow-up surveillance for post-colonoscopy CRC and more.
Read the full coverage here:
AGA releases 10 best practice statements for management of refractory celiac disease
Older patients with IBD at higher risk for treatment failure with vedolizumab
Follow-up surveillance within 5 years may detect post-colonoscopy CRC
Bulevirtide maintains safety, efficacy in HDV-related compensated cirrhosis at 72 weeks
PLX065 reduces liver fat content, prevents worsening of fibrosis in NASH
References:
Degasperi E, et al. Extension of bulevirtide monotherapy to 72 weeks in HDV patients with compensated cirrhosis: Efficacy and safety from the Italian multicenter study (HEP4Di). Presented at: The Liver Meeting; Nov. 4-8, 2022; Washington (hybrid).
Green PHR, et al. Gastroenterology. 2022;doi:10.1053/j.gastro.2022.07.086
Harrison SA, et al. PLX065 (deuterium-stabilized r-enantiomer of pioglitazone) reduces liver fat content and improves liver histology without PPAR gamma-mediated side effects in patients with NASH: Analysis of a 36-week placebo-controlled phase 2 trial (DESTINY1). Presented at: The Liver Meeting; Nov. 4-8, 2022; Washington (hybrid meeting).
Imperiale TF, et al. Abstract S245: Risk factors for 5-year post-colonoscopy colorectal cancers
(PCCRCs). Presented at: ACG Annual Scientific Meeting; Oct. 21-26, 2022; Charlotte, N.C. (hybrid meeting).
Singh S, et al. JAMA Netw Open. 2022;doi: 10.1001/jamanetworkopen.2022.34200.
In this edition, the importance of vaccination after cell therapy, artificial intelligence may help predict cardiotoxicity, experimental breast cancer vaccine generates immune response, and more.
Read the full coverage here:
Revaccination guidance after cell therapy established for some, ‘evolving’ for others
Artificial intelligence may help predict cardiotoxicity in renal cell carcinoma
Experimental breast cancer vaccine generates immune response to key tumor protein
Cancer cell therapy for melanoma has potential to save ‘thousands’ of lives each year
CAR-T regimen ‘should be new standard’ for high-risk B-cell acute lymphoblastic leukemia
References:
Disis ML, et al. JAMA Oncol. 2022;doi:10.1001/jamaoncol.2022.5143.
Sarnaik A, et al. Abstract 789. Presented at: Society for Immunotherapy of Cancer Annual Meeting; Nov. 8-12, 2022; Boston.
Saullo JL, et al. The importance of re-vaccination after cellular therapy. Presented at: NCCN 2022 Annual Congress: Hematologic Malignancies; Oct. 14-15, 2022; New York.
Wang T, et al. J Clin Oncol. 2022;doi:10.1200/JCO.22.01214
Yasin H, et al. Abstract 16. Presented at: International Kidney Cancer Symposium: North America; Nov. 4-5, 2022; Austin, Texas.
In this edition, neurologic effects of COVID-19 among pediatric populations, FDA accepts NDA for extended-release carbidopa/levodopa, antihistamines could be promising therapy for Parkinson’s disease and more.
Read the full coverage here:
Neurologic effects of COVID-19 persisted among pediatric populations in 2021
FDA accepts NDA for extended-release carbidopa/levodopa Parkinson’s treatment
Antihistamines could be promising adjuvant therapy for Parkinson’s disease
Recurrent head injury linked to affective dysregulation, impulse control
AI-powered detection tool found 85% of aneurysms were not referred for follow-up
References:
LaRovere KL, et al. JAMA Neurol. 2022;doi:10.1001/jamaneurol.2022.3881.
Press Release
Press Release
Richey LN, et al. M240. Associations of prior head injury with mild behavioral impairment domains. Presented at: American Neurological Association annual meeting; Oct. 23-25, 2022; Chicago.
Tandra G, et al. M189. Literature-based discovery to assess Parkinson’s disease adjuvants to levodopa. Presented at: American Neurological Association annual meeting; Oct. 23-25, 2022; Chicago.
In this episode, data show ‘critical need’ for universal genetic testing; patients with inflammatory breast cancer at high risk for brain metastases; palbociclib fails to benefit breast cancer subgroup and more.
Read the full coverage here:
Data show ‘critical need’ for universal genetic testing of patients with breast cancer
Patients with inflammatory breast cancer at high risk for brain metastases
Palbociclib fails to benefit breast cancer subgroup, yielding lessons for future research
Low-dose aspirin does not reduce breast cancer risk
Interventions improve cancer screening rates among women in rural areas
References:
Cairat M, et al. Abstract 1840. Presented at: World Cancer Congress; Oct. 18-20, 2022; Geneva.
DeMichele A, et al. Adjuvant palbociclib for ER+ breast cancer (PALLAS trial (ABCSG-42/AFT-05/PrE0109/BIG-14-13): A preplanned analysis of the stage IIA cohort. Presented at: ASCO Plenary Series; Oct. 18, 2022.
Paskett ED, et al. Abstract 1959. Presented at: World Cancer Congress; Oct. 18-20, 2022; Geneva.
Warren LEG, et al. Cancer. 2022;doi:10.1002/cncr.34441.
Whitworth PW, et al. JAMA Netw Open. 2022;doi:10.1001/jamanetworkopen.2022.32787.
In this edition, FDA approves Tecvayli for multiple myeloma, radiation and hormone therapy slows progression of prostate cancer, and more.
Read the full coverage here:
FDA approves Tecvayli for advanced multiple myeloma
Adding radiation to hormone therapy slows progression of oligometastatic prostate cancer
Use of cannabis during cancer treatment may have ‘under-appreciated’ financial impact
Older cancer survivors at higher risk for bone fracture
Machine-learning approach using step counts predicts hospitalization during radiotherapy
References:
Chino F, et al. Abstract 24. Presented at: ASCO Quality Care Symposium; Sept. 30-Oct. 1, 2022; Chicago.
Friesner I, et al. Abstract 132. Presented at: American Society for Radiation Oncology Annual Meeting; Oct. 23-26, 2022; New Orleans.
Press Release
Rees-Punia E, et al. JAMA Oncol. 2022;doi:10.1001/jamaoncol.2022.5153.
Tang C, et al. Abstract LBA 05. Presented at: American Society for Radiation Oncology Annual Meeting; Oct. 23-26, 2022; San Antonio.
In this edition, we bring you more news and Healio-exclusive interviews from the American Neurological Association Annual Meeting.
Read the full coverage here:
Diversity key to understanding genetics of neurodegenerative disease
Assessing chemical exposures key to understanding neuro diseases and disorders
VIDEO: Neurological complications can spur from certain infectious diseases
Age, specific pathology tied to shorter symptom duration in rapidly progressive dementia
Cognition in persons with epilepsy dependent on type, therapy model
References:
Asghar F et al. Cognition in persons with epilepsy: Differences based on disease type and therapy. Presented at: American Neurological Association annual meeting; Oct. 23-25; Chicago.
Cory-Slechta DA. Chemical exposures: The ignored environmental risk factors for neurodegenerative diseases and neurodevelopmental disorders. Presented at: American Neurological Association annual meeting; Oct. 23-25; Chicago.
Guerreiro R. The genetics of neurodegenerative diseases: from rare populations to common variants. Presented at: American Neurological Association annual meeting; Oct. 23-25, 2022; Chicago.
Lazar E, et al. Dissecting the neuropathological contributors to rapidly progressive dementia. Presented at: American Neurological Association annual meeting; Oct. 23-25; Chicago.
Saylor D, et al. A string of pearls: Key considerations in the care of neurological infections. Presented at: American Neurological Association annual meeting; Oct. 23-25, 2022; Chicago.
In this edition, Achalasia is associated with higher esophageal cancer risk; FDA rejects bulevirtide for hepatitis D and liver disease; real-world data on colonoscopy prep and more.
Read the full coverage here:
Achalasia associated with five-fold higher risk for esophageal cancer
FDA rejects Gilead’s bulevirtide for hepatitis D, compensated liver disease
Polyethylene glycol, ascorbic acid cleanse highly effective for colonoscopy prep
Distal cap-assisted endoscopic mucosal resection safe, effective for fibrotic polyps
FDA backs EndoStim’s neurostimulation implant for GERD control
References:
Arieira C, et al. Abstract S589: One-Liter Polyethylene Glycol + Ascorbic Acid Bowel Preparation Delivers High Levels of Adequate and High-Quality Bowel Cleansing for Colonoscopy. Presented at: ACG Annual Scientific Meeting; Oct. 21-26, 2022; Charlotte, N.C. (hybrid meeting).
Douglas SR, et al. Abstract S130: Distal Cap-Assisted Endoscopic Mucosal Resection Is a Safe and Effective Technique for Resection of Non-Lifting or Adherent Colorectal Polyps: An International, Multicenter, Retrospective Study. Presented at: ACG Annual Scientific Meeting; Oct. 21-26, 2022; Charlotte, N.C. (hybrid meeting).
Low EE, et al. Abstract S388: Risk of esophageal cancer in achalasia: A matched cohort study utilizing the veterans affairs achalasia cohort (VA-AC). Presented at: ACG Annual Scientific Meeting; Oct. 21-26, 2022; Charlotte, N.C. (hybrid meeting).
Press Release
Press Release
In this edition, we bring you news and Healio-exclusive interviews from the American Neurological Association Annual Meeting.
Read the full coverage here:
Optimism in older adults improves functional recovery after stroke
Neurologic, neurocognitive symptoms of COVID-19 persist for 1 year after diagnosis
VIDEO: Functional movement disorders diagnosed on presence of positive criteria
Pain, sleep, mood disorders most common comorbidities in patients with narcolepsy
VIDEO: Gene therapy potential treatment target for Duchenne muscular dystrophy
References:
Chamberlain J, et al. Neurogenetics and gene therapy. Presented at: American Neurological Association annual meeting; Oct. 23-25; Chicago.
Huff HV, et al. The neurologic and neurocognitive sequelae following COVID-19 in Lima, Peru: Presented at: American Neurological Association annual meeting; Oct. 23-25; Chicago.
Lipford MC, et al. Demographic characteristics and comorbidities of patients with narcolepsy: A propensity-score matched cohort study: Presented at: American Neurological Association annual meeting; Oct. 23-25; Chicago.
Reich SG, et al. Updates on functional neurological disorders. Presented at: American Neurological Association annual meeting; Oct. 23-25, 2022; Chicago.
Sloane KL, et al. Always look on the bright side: Associations of optimism with functional outcomes after stroke. Presented at: American Neurological Association annual meeting; Oct. 23-25; Chicago.
In this edition, COVID-19 patients at risk for post-infection complications; VR for patients with back pain; FDA requests further analysis of Supernus Parkinson’s treatment and more.
Read the full coverage here:
Evaluate headache characteristics to classify as migraine
FDA grants breakthrough device designation for brain implant technology
New genetic engineering company aims to develop neuroactive compounds from plants, fungi
Angiotensin receptor blocker therapy associated with decreased incidence of epilepsy
Theranica announces positive results from clinical trial for migraine treatment device
References:
Diamond M. Migraine, chronic migraine and medication overuse headache: Where are we today? Presented at: PAINWeek; Sept. 6-9, 2022; Las Vegas
Doege C, et al. JAMA Neurol. 2022;doi:10.1001/jamaneurol.2022.3413.
Press Release.
Press Release
Press Release
In this edition, AGA speaks out on controversial NordICC data; first US patient enrolled in phase 3 trial of obefazimod; ‘unprecedented’ shift in hepatitis A outbreaks and more.
Read the full coverage here:
AGA speaks out on controversial NordICC data citing modest colonoscopy benefit for CRC
First US patient enrolled in Abivax’s phase 3 trial of obefazimod for ulcerative colitis
Shift in hepatitis A outbreaks ‘unprecedented’ in HAV vaccine era, CDC reports
AGA releases first guideline ranking most effective anti-obesity medications
Inflammatory bowel disease may be causal risk for psoriasis, psoriatic arthritis
References:
Bretthauer M, et al. NEJM. 2022;doi:10.1056/NEJMoa2208375.
Foster MA, et al. MMWR Morb Mortal Wkly Rep. 2022;doi:10.15585/mmwr.mm7139a1.
Freuer D, et al. JAMA Dermatol. 2022;doi:10.1001/jamadermatol.2022.3682.
Grunvuld E, et al. Gastroenterology. 2022; doi: 10.1053/j.gastro.2022.08.045.
Press release
In this edition, COVID-19 patients at risk for post-infection complications; VR for patients with back pain; FDA requests further analysis of Supernus Parkinson’s treatment and more.
Read the full coverage here:
COVID-19 patients at risk for neurological complications 1 year post-infection
Patients with back pain benefited from at-home VR program
FDA requests further analysis of Supernus Parkinson’s treatment
Erenumab not effective at reducing pain in trigeminal neuralgia
Multiple factors indicate need for additional care after concussion
References:
Andersen ASS, et al. Lancet Neurol. 2022;doi:10.1016/S1474-4422(22)00294-0.
Hou BQ, et al. Clin J Sport Med. 2022;doi:10.1097/JSM.0000000000001057.
Maddox T, et al. At-home virtual reality program for chronic low back pain: Durability of a randomized, placebo-controlled trial to 18-months post-treatment. Presented at: PAINWeek; Las Vegas; Sept. 6-9, 2022.
Press Release
Xu E, et al. Nat Med. 2022;doi:10.1038/s41591-022-02001-z.
In this edition, preventive therapies should be offered for migraines; targeting neuropathic symptoms for poststroke pain; PDE5 inhibitors not associated with lower AD, dementia risk and more.
Read the full coverage here:
Range of preventive therapies should be offered for migraines
Poststroke pain may be controlled by targeting neuropathic symptoms
Treatment with PDE5 inhibitors not associated with reduced risk for AD, dementia
NFL, NFLPA finalize review of updated concussion protocol in wake of Tagovailoa injury
Blunt cerebrovascular injury increases risk for ischemic stroke, requires rapid response
References:
Bottros M. Poststroke pain: What it is, what causes it and how to treat it. Presented at: BRAINWeek; Sept. 28-30, 2022; Las Vegas.
Desai RJ, et al. Brain Commun. 2022;doi:10.1093/braincomms/fcac247.
Diamond M. Diamond Headache Clinic migraine track: Prevention, treatment. Presented at: BRAINWeek; Sept. 28-30, 2022; Las Vegas.
Press Release
Stone DK. Head and neck injury: Predictors of ischemic stroke. Presented at: BRAINWeek; Sept. 28-30, 2022; Las Vegas.
In this edition, endoscopic hemostasis system cleared by FDA for nonvariceal upper GI bleeding; Infliximab retreatment results in remission in patients with Crohn’s disease; men who have sex with men twice as likely to be diagnosed with IBD and more.
Read the full coverage here:
Endoscopic hemostasis system cleared by FDA for nonvariceal upper GI bleeding
Infliximab retreatment results in remission in 35% of patients with Crohn’s disease
Men who have sex with men twice as likely to be diagnosed with IBD
Obeticholic acid yields fewer deaths, liver transplants in primary biliary cholangitis
Third COVID vaccine provides ‘significant boost’ in antibody response in patients with IBD
References:
Alexander JL, et al. Lancet Gastroenterol Hepatol. 2022;doi:10.1016/S2468-1253(22)00274-6.
Boschetti G, et al. Am J Gastroenterol. 2022;doi:10.14309/ajg.0000000000001842.
Mansoor E, et al. Gut. 2022;doi:10.1136/gutjnl-2022-328218.
Murillo Perez CF, et al. Gastroenterology. 2022;doi:10.1053/j.gastro.2022.08.054.
Press Release
In this episode, FDA approves Rolvedon to reduce infection incidence; women want more education on sexual health during treatment; abemaciclib regimen shows further signs of benefit and more.
Read the full coverage here:
FDA approves Rolvedon to reduce infection incidence when taking certain anticancer drugs
Women with breast cancer want more education on sexual health during treatment
Abemaciclib regimen shows further signs of benefit in advanced breast cancer subgroup
Cancer-related fatigue may impact balance after breast cancer treatment
Chronic inflammation linked to cognitive difficulties among older breast cancer survivors
References:
Carroll JE, et al. J Clin Oncol. 2022;doi:10.1200/JCO.22.00406.
Goetz MP, et al. Abstract LBA15. Presented at: European Society for Medical Oncology Congress. Sept. 9-13, 2022; Paris.
Huynh V, et al. Ann Surg Oncol. 2022;doi:10.1245/s10434-022-12126-7.
Press Release
Wechsler S, et al. Rehab Oncol. 2022;doi:10.1097/01.REO.0000000000000308.
In this edition, lecanemab study shows reduction in clinical decline for early AD; multimorbidity associated with increased risk for dementia, Crenezumab not effective in treating Alzheimer's disease and more.
Read the full coverage here:
Phase 3 study of lecanemab shows reduction in clinical decline in patients with early AD
Multimorbidity associated with increased risk for dementia
Crenezumab not effective in treating Alzheimer's disease
FDA approves macrocyclic GBCA for contrast-enhanced MRI
Healthy habits in midlife may help delay onset of cognitive decline
References:
Calvin CM, et al. JAMA Netw Open. 2022;doi:10.1001/jamanetworkopen.2022.32124.
Ostrowitzki S, et al. JAMA Neurol. 2022;doi:10.1001/jamaneurol.2022.2909.
Press Release
Press Release
Small G. What’s preventing us from preventing dementia? Presented at: BRAINWeek; Sept. 28-30, 2022; Las Vegas.
In this edition, splash pads reduce child drowning risk but boost diarrhea outbreaks; FDA approves Konvomep for benign gastric ulcers; Xifaxan generic may be stalled until 2029 and more.
Read the full coverage here:
‘The water is recycled’: Splash pads reduce child drowning risk, boost diarrhea outbreaks
FDA approves Konvomep for benign gastric ulcers, risk reduction for upper GI bleeding
Xifaxan generic may be stalled until 2029 despite tentative FDA approval
Earlier CRC screening with colonoscopy, FIT cost-effective ‘irrespective of BMI’
1-year surveillance endoscopy recommended for patients at high risk for gastric cancer
References:
Aluko SK, et al. MMWR Morb Mortal Wkly Rep. 2022;doi:10.15585/mmwr.mm7131a1
Press Release
Press Release
Yamamoto Y, et al. JAMA Netw Open. 2022;doi:10.1001/jamanetworkopen.2022.27667.
Yeoh A, et al. Clin Gastroenterol Hepatol. 2022;doi:10.1016/j.cgh.2022.07.028.
In this edition, FDA votes to support approval of ALS therapy; partnership offers military veterans access to psychedelics; epidural steroid injections as alternate pain management options and more.
Read the full coverage here:
FDA advisory committee votes to support approval of ALS therapy
Partnership offers military veterans access to psychedelics at home, abroad
Epidural steroid injection an alternate pain management option
Ketamine may be effective in treating children with ADNP syndrome
FDA accepts new drug application for Rett syndrome treatment
References:
Christo PJ. Landscape of wonders: Injections, nerve blocks, pumps and neuromodulation. Presented at: PAINWeek; Las Vegas; Sept. 9-12, 2022.
Kolevzon A, et al. HGG Adv. 2022;doi:10.1016/j.xhgg.2022.100138.
Press Release
Press Release
Press Release
In this edition, new cannabinoids hold promise for medical applications; Theranica secures $45 million for migraine treatment device and more.
Read the full coverage here:
Newly discovered cannabinoids hold promise for medical, pain applications
Theranica secures $45 million to expand wearable migraine treatment device in US
Implantable loop recorder screening for AF not linked to stroke reduction risk
Survey shows OTC pain relievers remain ‘common, valuable’
Amneal submits new drug application for extended-release Parkinson’s treatment
References:
Diederichsen SZ et al. JAMA Neurol. 2022;doi:10.1001/jamaneurol.2022.3031.
Guglieri M et al. JAMA Neurol. 2022;doi:10.1001/jamaneurol.2022.2480.
Jacknin J. How green is my valley: Newly discovered cannabinoids and their possible medical uses. Presented at: PAINWeek; Las Vegas; Sept. 6-9, 2022.
Press Release
Press Release
In this edition, germline testing ‘should be considered’ for all patients with lung cancer; phase 3 trial of canakinumab misses endpoint; sexual dysfunction common among women with lung cancer, and more.
Read the full coverage here:
Germline testing ‘should be considered’ for all patients with lung cancer, data suggest
Phase 3 trial of canakinumab for non-small cell lung cancer misses endpoint
Sexual dysfunction common among women with lung cancer
Younger patients with lung cancer more likely to have advanced disease at diagnosis
Sotorasib extends PFS in lung cancer subset
References:
Florez N, et al. Abstract MA14. Presented at: International Association for the Study of Lung Cancer World Conference on Lung Cancer (hybrid meeting); Aug. 6-9, 2022; Vienna.
Potter A, et al. Abstract OA05. Presented at: International Association for the Study of Lung Cancer World Conference on Lung Cancer (hybrid meeting); Aug. 6-9, 2022; Vienna.
Press Release
Press Release
Sorscher S, et al. Abstract 388570. Presented at: ASCO Plenary Series (virtual); Aug. 16, 2022.
In this episode, VTE rate with abemaciclib (uh-bem-uh-cy-clib) higher in real-world setting; Enhertu extends progression-free survival in patient subgroup; FDA grants priority review to elacestrant (ee-las-cess-trant) for metastatic disease; and more.
Read the full coverage here:
VTE rate with abemaciclib higher in real-world setting among patients with breast cancer
Enhertu extends progression-free survival in breast cancer subgroup, topline data show
FDA grants priority review to elacestrant for metastatic breast cancer
Lack of financial comfort linked to weight gain among young breast cancer survivors
Hispanic ethnicity often not reported in breast cancer studies
References:
Bazan JG, et al. JAMA Oncol. 2022;doi:10.1001/jamaoncol.2022.3527.
Press Release
Press Release
Sella T, et al. Cancer. 2022;doi:10.1002/cncr.34342.
Watson NW, et al. Cancer. 2022.doi:10.1002/cncr.34367.
In this edition, blood-based concussion diagnostic tool gets patent; examining the brain’s electrical signals may be key to treating epilepsy, schizophrenia; machine-learning model may predict best antiseizure medications and more.
Read the full coverage here:
Neurolytixs secures US patent for blood-based concussion diagnostic tool
Examination of brain’s electrical signals may be key to treating epilepsy, schizophrenia
Machine-learning model may predict which antiseizure medications work best
Rafa receives FDA approval for autoinjector to treat status epilepticus in adults
Aptinyx completes enrollment of phase 2 trial for oral cognitive impairment treatment
References:
Hakeem H, et al. JAMA Neurol. 2022;doi:10.1001/jamaneurol.2022.2514.
Press Release
Press Release
Press Release
Press Release
In this edition, BMI is associated with dementia in women and linked with disease in men; Healthy diet, physical activity are linked to lower mortality in adults with PD; mild TBI and CT scans and more.
Read the full coverage here:
High BMI negatively associated with dementia in women, low BMI linked with disease in men
Healthy diet, physical activity linked to lower mortality rate in adults with PD
Patients with mild TBI, negative CT scan should be evaluated 2 weeks after injury
FDA approves spinal cord stimulation system for broad treatment of chronic pain
Artificial intelligence model detects Parkinson’s disease via nocturnal breathing signals
References:
Jacob L, et al. J Alzheimers Dis. 2022;doi:10.3233/JAD-220147.
Madhok DY, et al. JAMA Netw Open. 2022;doi:10.1001/jamanetworkopen.2022.23245.
Press Release
Yang Y, et al. Nat Med. 2022;doi:10.1038/s41591-022-01932-x.
Zhang X et al. JAMA Netw Open. 2022;doi:10.1001/jamanetworkopen.2022.27738.
In this edition, macular retinal nerve fiber layer thickness linked with cognitive decline; FDA approves Lucentis biosimilar; advanced visual field loss risk higher after glaucoma diagnosis in Black patients; and more.
Association found between macular retinal nerve fiber layer thickness, cognitive decline
FDA approves Cimerli as interchangeable biosimilar to Lucentis
Black patients have higher risk for advanced visual field loss after glaucoma diagnosis
iStent infinite cleared by FDA
Alcon to acquire Aerie Pharmaceuticals
References:
Kang JH, et al. Transl Vis Sci Technol. 2022;doi:10.1167/tvst.11.7.21.
Kim HM, et al. JAMA Ophthalmol. 2022;doi:10.1001/jamaophthalmol.2022.1563.
Press Release
Press Release
Press Release
In this edition, leisure activities may lower risk for Alzheimer's disease and dementia; most common long COVID symptoms include fatigue and headache; ‘life-changing’ app-based digital therapeutic for tinnitus and more.
Read the full coverage here:
Leisure activities may lower risk for Alzheimer's disease, dementia
Fatigue, headache most common long COVID symptoms
Personalized, app-based digital therapeutic for tinnitus ‘life-changing’
NIH to fund development, testing of robots to aid in Alzheimer's disease care
AI algorithm detects brain abnormalities, could help treat epilepsy
References:
Chen AK, et al. Brain Behav Immun. 2022;doi:10.1016/j.bbih.2022.100491
Press Release
Searchfield GD, et al. Front Neurol. 2022;doi:10.3389/fneur.2022.958730
Spitzer H, et al. Brain. 2022;doi:10.1093/brain/awac224
Su S, et al. Neurology. 2022;doi:10.1212/WNL.0000000000200929
In this edition, light stimulation may help delay Alzheimer’s progression; sleep EEGs may predict future disease and mortality; updated data on the prevalence of tinnitus and more.
Read the full coverage here:
Light stimulation may help delay AD progression, more research needed in older adults
Sleep EEGs may predict future disease, mortality
Tinnitus affects more than 740 million adults globally
Gut-based neurotoxin triggers inflammation associated with Alzheimer's disease
CSF biomarkers support AD diagnosis in nearly 90% of clinical cases
References:
Agüero P, et al. CSF Alzheimer’s biomarkers in clinical practice. Presented at: Alzheimer’s Association International Conference; July 31-Aug. 4; San Diego.
Beckers E, et al. Characterization of pupillary responses to alternating blue and orange light exposures in a fMRI protocol. Presented at: Alzheimer’s Association International Conference; July 31-Aug. 4; San Diego.
Jarach CM, et al. JAMA Neurol. 2022;doi:10.1001/jamaneurol.2022.2189.
Pogue AI, et al. Front Neurol. 2022;doi:10.3389/fneur.2022.900.048
Sun H, et al. Predicting incident outcomes from the microstructure of sleep. Presented at: SLEEP; June 5-8, 2022; Charlotte, N.C.
In this edition, lung cancer risk is high among smokers for whom screening is not recommended; the role of circulating tumor DNA in lung cancer detection and treatment is 'exciting' for field; a subset of patients with lung cancer have poor response to COVID-19 vaccines, and more.
Read the full coverage here:
Lung cancer risk high among smokers for whom screening is not recommended
Role of circulating tumor DNA in lung cancer detection, treatment 'exciting' for field
Subset of patients with lung cancer have poor response to COVID-19 vaccines
Low area-level income, education linked to higher odds of late-stage lung cancer diagnosis
Phase 3 trial of Onivyde for small cell lung cancer misses endpoint
References:
Faselis C, et al. JAMA Oncol. 2022;doi:10.1001/jamaoncol.2022.2952.
Gupta A, et al. Cancer. 2022;doi:10.1002/cncr.34327.
Healio Interview
Press Release
Valanparambil RM, et al. J Clin Oncol. 2022;doi:10.1200/JCO.21.02986.
In this edition, physicians should question patients with restless leg syndrome about cannabis use ; digital therapeutic improves symptoms of insomnia, anxiety and depression; more efficient sleep may benefit patients with fibromyalgia and insomnia and more.
Read the full coverage here:
Physicians should question patients with restless leg syndrome about cannabis use
Digital therapeutic improves symptoms of insomnia, anxiety, depression for 6 months
More efficient sleep may benefit patients with fibromyalgia, insomnia
FDA accepts new drug application, grants priority review for ALS treatment
Quanterix announces validation of biomarker detection test to aid in diagnosis of AD
References:
Kachechian T, et al. Prevalence of cannabis use in patients with restless leg syndrome for symptomatic relief. Presented at: SLEEP; June 5-8, 2022; Charlotte, N.C.
Nair N, et al. Effect of sleep on the relationship between pain-related disability and neural correlates of pain processing in adults with fibromyalgia and insomnia. Presented at: SLEEP; June 5-8, 2022; Charlotte, N.C.
Press Release
Press Release
Press Release
In this episode, menopausal hormone therapy is not associated with breast cancer recurrence and mortality; pandemic-related screening declines may result in ‘increased avoidable cancer deaths’; data on pertuzumab regimen in early breast cancer; and more.
Read the full coverage here:
Menopausal hormone therapy not associated with breast cancer recurrence, mortality
Screening declines after pandemic onset may result in ‘increased avoidable cancer deaths’
Updated data show long-term benefit with pertuzumab regimen in early breast cancer
Medical financial hardship linked to increased mortality risk among cancer survivors
FDA grants priority review to Enhertu for HER2-low metastatic breast cancer
References:
Cold S, et al. J Natl Cancer Inst. 2022;doi:10.1093/jnci/djac112.
Press Release
Press Release
Teglia F, et al. JAMA Oncol. 2022;doi:10.1001/jamaoncol.2022.2617.
Yabroff KR, et al. J Natl Cancer Inst. 2022;doi:10.1093/jnci/djac044.
In this edition, temperature-controlled mattresses and pillows improve sleep; how overturning Roe v. Wade affects the field of neurology; college students’ cognition altered by changing sleep patterns and more.
Read the full coverage here:
Temperature-controlled mattress, pillow improve sleep onset, quality
Decision to overturn Roe v. Wade will ‘undoubtedly’ affect those in the field of neurology
Changing sleep patterns affect cognition in college students
FDA grants tentative approval for daytime sleepiness treatment
Study shows people with migraines have lower risk for sleep apnea
References:
Costa A, et al. Daily patterns of sleep and metacognition in college students. Presented at: SLEEP; June 5-8, 2022; Charlotte, N.C.
Gruenthal E, et al. Polysomnographic biomarkers of sleep disruption and sleep disordered breathing in migraine: A large matched case control clinical registry-based study. Presented at: SLEEP; June 5-8, 2022; Charlotte, N.C.
Haghayegh S, et al. J Sleep Res. 2022;doi:10.1111/jsr.13662.
LaHue SC, et al. JAMA Neurol. 2022;doi:10.1001/jamaneurol.2022.2347.
Press Release
In this week’s edition, a Labcorp blood test identifies signs of neurodegenerative disease; the FDA approves an oral treatment for partial seizures in teens; ketamine shows efficacy in epilepsy; and more.
Read the full coverage here:
Labcorp blood test identifies signs of neurodegenerative disease
FDA approves oral treatment for partial seizures in patients aged 16 years and older
Ketamine effective treatment for neonatal, pediatric epilepsy
FDA places hold on phase 2/3 clinical trial of stroke therapy
Hypertension, obesity, physical inactivity among highest risk factors for dementia
References:
Jacobwitz M, et al. Neurology. 2022;doi:10.1212/WNL.0000000000200889.
Lee M, et al. JAMA Netw Open. 2022;doi:10.1001/jamanetworkopen.2022.19672.
Press Release
Press Release
Press Release
In this week’s edition, Break Through Cancer awards $50M to fund a ‘radical collaboration’ in cancer research; the FDA grants a breakthrough device designation for an MS plasma test; App-based mental exercises may improve cognitive impairment; and more.
Read the full coverage here:
Break Through Cancer awards $50M to fund ‘radical collaboration’ in cancer research
FDA grants breakthrough device designation for MS plasma test
App-based mental exercises improve cognitive impairment
Neurodevelopment in infants with CHD may be predicted in utero
Benefits of ticagrelor, aspirin for stroke outweigh risks over 30 days
References:
Press Release
Press Release
Press Release
Healio Interview
Wang Y, et al. Neurology. 2022;doi:10.1212/WNL.0000000000200355.
In this edition, Iveric Bio is given exclusive permission to develop, commercialize new formulations of Zimura; subretinal drusenoid deposits linked with cardiovascular disease; subcutaneous elamipretide may improve visual function in geographic atrophy; and more.
Read the full coverage here:
Iveric Bio given exclusive permission to develop, commercialize new formulations of Zimura
Subretinal drusenoid deposits linked with cardiovascular disease
Subcutaneous elamipretide may improve visual function in geographic atrophy
Combination technique useful for treating myopic traction maculopathy
Insufficient treatment common among patients with wet AMD
References:
Barikian A, et al. Characteristics and outcomes of patients with nAMD managed in US routine clinical practice: An analysis of the IRIS Registry database. Presented at: American Society of Retina Specialists annual meeting; July 13-16, 2022; New York.
Chew FM, et al. Scleral imbrication with combined pars plana vitrectomy and foveal sparing ILM peel as a useful surgical modality in treating myopic traction maculopathy. Presented at: American Society of Retina Specialists annual meeting; July 13-16, 2022; New York.
Heier JS. ReCLAIM-2 study results: A phase 2 study of elamipretide safety & efficacy in geographic atrophy. Presented at: American Society of Retina Specialists annual meeting; July 13-16, 2022; New York.
Press Release
Thompson RJ, et al. Retina. 2022;doi:10.1097/IAE.0000000000003460.
In this edition, Incidental respiratory findings on low-dose CT lung cancer screening common; lack of guideline-concordant treatment for early-stage non-small cell lung cancer common; women at greater risk for more severe adverse events from cancer treatments, and more.
Read the full coverage here:
Incidental respiratory findings on low-dose CT lung cancer screening common
Lack of guideline-concordant treatment for early-stage non-small cell lung cancer common
Women at greater risk for more severe adverse events from cancer treatments
Visual, quantitative CT emphysema assessments linked to higher odds of lung cancer
Acetaminophen may reduce immunotherapy efficacy in patients with cancer
References:
Bessede A, et al. Abstract LBA12000. Presented at: ASCO Annual Meeting; June 3-7, 2022; Chicago.
Kehl KL, et al. JAMA Oncol. 2022;doi: 10.1001/jamaoncol.2022.0039.
Pinsky PF, et al. Chest. 2022;doi:10.1016/j.chest.2021.11.015.
Unger JM, et al. J Clin Oncol. 2022;doi:10.1200/JCO.21.02377.
Yang X, et al. Radiol. 2022;doi:10.1148/212904.
In this week’s edition, women are less likely than men to return to work after large vessel occlusion stroke; cognitive impairment, headaches and CVD are more common in former college football players; veterans, providers support the addition of integrative medicine for chronic headaches; and more.
Read the full coverage here:
Women less likely than men to return to work after large vessel occlusion stroke
Cognitive impairment, headaches, CVD more common in former college football players
Veterans, providers support addition of integrative medicine for chronic headaches
New blood biomarker may lead to early diagnosis of frontotemporal dementia
Phase 2 trial shows promising results for oral Parkinson’s treatment
References:
Hahn M, et al. Stroke. 2022;doi:10.1161/STROKEAHA.121.037386.
Phelps A, et al. JAMA Netw Open. 2022;doi:10.1001/jamanetworkopen.2022.8775.
Press Release
Press Release
Press Release
In this edition, late-stage colorectal, breast cancer diagnoses increase after start of COVID-19 pandemic; chemicals found in hair products increase viability of breast cancer cells in Black women; continued CDK 4/6 inhibition after breast cancer progression may benefit some patients; and more.
Read the full coverage here:
Late-stage colorectal, breast cancer diagnoses increase after start of COVID-19 pandemic
Chemicals found in hair products increase viability of breast cancer cells in Black women
Continued CDK 4/6 inhibition after breast cancer progression may benefit some patients
Some older women with luminal A breast cancer can safely forgo radiotherapy, study shows
Sacituzumab govitecan significantly extends PFS in advanced breast cancer subset
References:
Zhou JZ, et al. JAMA Netw Open. 2022;doi:10.1001/jamanetworkopen.2021.48581.
Trevino L, et al. RF22 | PMON05. Presented at: ENDO Annual Meeting; June 11-14, 2022; Atlanta (hybrid meeting).
Kalinsky K, et al. Abstract LBA1004. Presented at: ASCO Annual Meeting; June 3-7, 2022; Chicago.
Source: Whelan TJ, et al. Abstract LBA501. Presented at: ASCO Annual Meeting; June 3-7, 2022; Chicago.
Rugo HS, et al. Abstract LBA1001. Presented at: ASCO Annual Meeting; June 3-7, 2022; Chicago.
In this week’s edition, CAR-T ‘robustly effective’ in younger patients with deadly form of brain cancer; SARS-CoV-2 linked to range of neurological diseases; Increased mortality risk for men with type 1 diabetes, regardless of cognitive ability; and more.
Read the full coverage here:
Steerable microcatheter nets FDA 510(k) clearance for neurologic, peripheral, coronary use
CAR-T ‘robustly effective’ in younger patients with deadly form of brain cancer
SARS-CoV-2 linked to range of neurological diseases
Risk for major adverse CV events elevated with type 2 diabetes, cognitive impairment
Increased mortality risk for men with type 1 diabetes, regardless of cognitive ability
References:
Press Release
Majzner RG, et al. Abstract CT001. Presented at: American Association for Cancer Research Annual Meeting; April 8-13, 2022; New Orleans.
Klein RS, et al. Neurobiology of COVID-19. Presented at: American Academy of Neurology annual meeting; April 2-7, 2022; Seattle.
Cukierman-Yaffe T, et al. J Clin Endocrinol Metab. 2022;doi:10.1210/clinem/dgac200
Dybjer E, et al. Diabet Med. 2022;doi:10.1111/dme.14806.
In this edition, AYA cancer survivors are at higher risk for death due to second primary cancers; a radiation technique reduces symptomatic esophagitis in patients with advanced lung cancer; a phase 3 trial of tiragolumab plus atezolizumab misses its co-primary endpoint; and more.
Read the full coverage here:
AYA cancer survivors at higher risk for death due to second primary cancers
Radiation technique reduces symptomatic esophagitis in patients with advanced lung cancer
Phase 3 trial of combination for advanced lung cancer misses co-primary endpoint
As proton beam therapy use for cancer increased, ‘so did the racial disparity in receipt’
Entrectinib induces durable, intracranial responses in NTRK fusion-positive solid tumors
References:
Sung H, et al. J Natl Cancer Inst. 2022;doi:10,1093/jnci/djac091.
Louie AV, et al. JAMA Oncol. 2022:doi:10.1001/jamaoncol.2021.7664.
Press Release
Nogueira LM, et al. JAMA Netw Open. 2022;doi:10.1001/jamanetworkopen.2022.8970.
Demetri GD, et al. Clin Cancer Res. 2022;doi:10.1158/1078-0432.CCR-21-3597.
In this week’s edition, anxiety, depression worse among older men with vision impairment; emerging therapeutics may improve outcomes in pediatric patients with rare disorders; glioblastoma presents roadblock to successful immunotherapy; and more.
Read the full coverage here:
MRI findings key pathology markers of 4R-tauopathies
Emerging therapeutics may improve outcomes in pediatric patients with rare disorders
Together Senior Health launches platform to reduce memory loss in AD, dementia
Anxiety, depression worse among older men with vision impairment
Glioblastoma presents roadblock to successful immunotherapy
References:
Carlos AF, et al. Tau histopathological lesion type correlates of structural magnetic resonance imaging and diffusion tensor imaging biomarkers in 4-repeat tauopathies. Presented at: American Academy of Neurology annual meeting; April 2-7, 2022; Seattle.
Emrick L, et al. Emerging therapeutics for rare pediatric genetic disorders. Presented at: American Academy of Neurology annual meeting; April 2-7, 2022; Seattle.
Press Release
Gascoyne B, et al. Int Health. 2022;doi:10.1093/inthealth/ihab070
Kumthekar P. AAN year in review: neuro oncology. Presented at: American Academy of Neurology annual meeting; April 2-7, 2022; Seattle.
Read the full coverage here:
In this edition, diet, genetics and family history play role in AMD progression; omega-3 fatty acids may improve vision in dry AMD; long-term dopamine treatment may delay onset of diabetic retinopathy; and more.
Diet, genetics and family history play role in AMD progression
Omega-3 fatty acids may improve vision in dry AMD
Long-term dopamine treatment may delay onset of diabetic retinopathy
Anti-VEGF injections decrease aqueous VEGF levels in diabetic retinopathy
Novel ERG method aids in monitoring patients with posterior uveitis
References:
Williams BK. What to do for your patient with early dry AMD. Presented at: American Society of Cataract and Refractive Surgery meeting; April 22-26, 2022; Washington.
Prokopiou E, et al. A prospective, randomised, multicenter, double-blind, placebo-controlled study assessing the potential effects of omega-3 fatty acids supplementation on dry age-related macular degeneration and Stargardt disease. Presented at: Association for Research in Vision and Ophthalmology meeting; May 1-4, 2022; Denver.
Allen RS, et al. Dopamine treatment delays diabetic retinopathy onset in a retrospective study. Presented at: Association for Research in Vision and Ophthalmology meeting; May 1-4, 2022; Denver.
Mynampati BK, et al. Aqueous levels of VEGF decrease after serial intravitreal injections of anti-VEGF agents in patients with diabetic retinopathy. Presented at: Association for Research in Vision and Ophthalmology meeting; May 1-4, 2022; Denver.
Than NTT, et al. Flicker ERG findings in posterior uveitis. Presented at: Association for Research in Vision and Ophthalmology meeting; May 1-4, 2022; Denver.
In this week’s edition, childhood sexual and emotional abuse increases the risk for multiple sclerosis in women; fentanyl-related cardiac arrest is linked to worse neurological outcomes; Black patients with MS have a higher rate of disability compared with their white counterparts; and more.
Read the full coverage here:
Childhood sexual, emotional abuse increases multiple sclerosis risk in women
Fentanyl-related cardiac arrest linked to worse neurological injury, outcomes
Black MS patients have higher rate of disability than white counterparts
Brain stimulation software receives FDA approval for use in Parkinson’s disease
Seizure frequency, poor quality of life risk factors for depression in epilepsy patients
References:
Eid K, et al. J Neurol Neurosurg Psychiatry. 2022;doi:10.1136/jnnp-2021-328700.
Otero M, et al. Neurological injury and outcomes in fentanyl-related cardiac arrest. Presented at: American Academy of Neurology annual meeting; April 2-7, 2022; Seattle.
Dykes E, et al. Health disparities in African American patients with multiple sclerosis: a retrospective chart-review study. Presented at: American Academy of Neurology annual meeting; April 2-7, 2022; Seattle.
Press Release
Syed M, et al. Factors associated with depression in epilepsy patients: a population-based study in the Detroit metropolitan area. Presented at: American Academy of Neurology annual meeting; April 2-7, 2022; Seattle.
In this edition, early lung cancer detection improves survival rates; incidental respiratory findings on low-dose CT lung cancer screening common; certain patients may derive more benefit from immunotherapy for non-small cell lung cancer and more.
Read the full coverage here:
Early lung cancer detection improves survival rates
Incidental respiratory findings on low-dose CT lung cancer screening common
Certain patients may derive more benefit from immunotherapy for non-small cell lung cancer
Bispecific antibody shows durable benefit in advanced solid tumors
Enhertu receives priority review for HER2-mutated non-small cell lung cancer
References:
Healio Interview
Pinsky PF, et al. Chest. 2022;doi:10.1016/j.chest.2021.11.015.
Patel K, et al. JNCI Cancer Spectr. 2022;doi:10.1093/jncics/pkac015
Bispecific antibody shows durable benefit in advanced solid tumors
Press Release
In this week’s edition, risk for cognitive decline is associated with older COVID-19 survivors; a study validates an FDA-approved blood test for traumatic brain injury; and more.
Read the full coverage here:
Risk for cognitive decline associated with older COVID-19 survivors
Study validates FDA-approved blood test for traumatic brain injury
VA hospital telestroke networks improve treatment, lower ED transfer rate
Lower left atrial function associated with higher risk for dementia
Rates of neurological events higher with SARS-CoV-2 infection than with COVID-19 vaccine
References:
Liu YH, et al. JAMA Neurol. 2022;doi:10.1001/jamaneurol.2022.0461.
Papa L, et al. JAMA Netw Open. 2022;doi:10.1001/jamanetworkopen.2022.1302.
Lyerly M, et al. Neurology. 2022;doi:10.1212/WNL.0000000000200143.
Wang W, et al. JAMA. 2022;doi:10.1001/jama.2022.2518
Li X, et al. BMJ. 2022;doi:10.1136/bmj-2021-068373.
In this edition, European commission approves Beovu for DME, choroidal vascularity index linked with geographic atrophy progression, intravitreal gene therapy effective, safe in Leber hereditary optic neuropathy, and more.
Read the full coverage here:
Susvimo noninferior to monthly ranibizumab with similar efficacy
European Commission approves Beovu for DME
Intravitreal gene therapy effective, safe in Leber hereditary optic neuropathy
Teprotumumab may provide better outcomes than IV methylprednisolone in thyroid eye disease
Choroidal vascularity index linked with geographic atrophy progression
References:
Healio Interviews
Holekamp NM, et al. Ophthalmology. 2022;doi:10.1016/j.ophtha.2021.09.016.
Newman N, et al. The Phase III REFLECT Trial: Efficacy and safety of bilateral gene therapy for Leber hereditary optic neuropathy (LHON). Presented at: American Academy of Neurology Annual Meeting; April 2-7, 2022; Seattle.
Press Release
Sacconi R, et al. Retina. 2022;doi:10.1097/IAE.0000000000003305.
In this week’s edition, the FDA approval of an oral anticonvulsant; plus news you may have missed from the AAN and ACTRIMS meetings.
Read the full coverage here:
FDA approves oral anticonvulsant
New drug improved tic severity in children with Tourette syndrome
Vitamin D levels not associated with adverse outcomes in European MS patients
Zolpidem may be effective for prolonged disorders of consciousness
Amygdala overgrowth begins in first year of life in infants with ASD
References:
Press Release
Gilbert DL, et al. ES1.002: Ecopipam in children and adolescents with Tourette syndrome: Results from a randomized, double-blind, placebo-controlled phase 2b study. Presented at: American Academy of Neurology annual meeting; April 2-7, 2022; Seattle.
Vasileiou E, et al. Vitamin D polygenic score and multiple sclerosis outcomes. Presented at: ACTRIMS Forum; Feb. 24-26; West Palm Beach, Florida.
Cassidy J, et al. Impact of zolpidem in the treatment of prolonged disorders of consciousness. Presented at: American Academy of Neurology annual meeting; April 2-7, 2022; Seattle.
Shen MD, et al. Am J Psychiatry. 2022;doi:10.1176/appi.ajp.21090896
Disclosures: Please see each study for relevant financial disclosures.
In this edition, digital imaging and AI advance investigation of systemic disease through the retina; handheld retinal imaging devices may have utility in screening; Xipere launches in the US; and more.
Read the full coverage here:
Digital imaging, AI advance investigation of systemic disease through the retina
No additional visual benefit seen with nesvacumab-aflibercept combination in DME
Soft drusen, subretinal drusenoid deposits may be separate diseases leading to AMD
Xipere launches in US
Handheld retinal imaging devices may have utility in screening
References:
Healio Interviews
Brown DM, et al. Retina. 2022;doi:10.1097/IAE.0000000000003441.
Thomson RJ, et al. Retina. 2022;doi:10.1097/IAE.0000000000003460.
Press Release
Salongcay RP, et al. Ophthalmol Retina. 2022;doi:10.1016/j.oret.2022.03.002
In this edition, a phase 3 trial of a regimen for small cell lung cancer misses its co-primary endpoint; obesity and pulmonary function may identify the need for home oxygen after lung cancer surgery; a study finds that lung cancer screening is less common among those most likely to benefit from it; and more.
Read the full coverage here:
Phase 3 trial of regimen for small cell lung cancer misses co-primary endpoint
Obesity, pulmonary function may identify need for home oxygen after lung cancer surgery
Lung cancer screening less common among those most likely to benefit from it
FDA rejects sintilimab with chemotherapy for non-small cell lung cancer
Blood-based microRNA signature may predict survival in immunotherapy-treated NSCLC
References:
Press Release
Nicastri DG, et al. Ann Am Thorac Soc. 2022;doi:10.1513/AnnalsATS.202103-231OC.
Rustagi AS, et al. JAMA Netw Open. 2022;doi:10.1001/jamanetworkopen.2022.5318.
Press Release
Rajakumar T, et al. npj Precis Oncol. 2022;doi:10.1038/s41698-022-00262-y.
This week, a speaker predicts the AMD epidemic will continue to challenge ophthalmologists; pegcetacoplan results in 18-month reduction in GA lesion growth; interim trial results show efficacy of photo-bio-modulation in dry AMD; and more.
Read the full coverage here:
AMD epidemic will continue to challenge ophthalmologists
Reduction in GA lesion growth continues at 18 months with pegcetacoplan
Interim trial results show efficacy of photobiomodulation in dry AMD
Ophthalmological manifestations observed in one-third of COVID-19 cases at single center
PDT may be effective for choroidal metastasis treatment
References:
Chew EY. Irving H. Leopold Lecture: Age-related macular degeneration: What have we learned from the age-related eye disease study (AREDS) and AREDS2? Presented at: Wills Eye Conference; March 10-12, 2022; Philadelphia.
Press Release
Press Release
Romero-Castro RM, et al. Retina. 2022;doi:10.1097/IAE.0000000000003457.
Sacconi R, et al. Retina. 2022;doi:10.1097/IAE.0000000000003305.
In this week's addition, the FDA approval of a transdermal patch to treat Alzheimer’s-related dementia; the link between daily napping among older adults and an increased risk for Alzheimer’s disease; an oral treatment for Parkinson’s demonstrated positive phase 2 results; and more.
Read the full coverage here:
FDA approves transdermal patch to treat Alzheimer’s-related dementia
Daily napping among older adults linked to a 40% higher risk for Alzheimer’s disease
Oral treatment for Parkinson’s shows positive phase 2 results
Sleep academy warns lawmakers about health risks of permanent daylight saving time
AAN: Medication, exercise more beneficial than stent in preventing stroke
References:
Press Release
Li P, et al. Alzheimers Dement. 2022;doi:10.1002/alz.12636.
Press Release
Press Release
Turan TN, et al. Neurology. 2022;doi:10.1212/WNL.0000000000200030.